<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibodies (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibodies (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">3697</journal-id><journal-id journal-id-type="pmc-domain">antibodies</journal-id><journal-id journal-id-type="publisher-id">antibodies</journal-id><journal-title-group><journal-title>Antibodies</journal-title></journal-title-group><issn pub-type="epub">2073-4468</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10295010</article-id><article-id pub-id-type="pmcid-ver">PMC10295010.1</article-id><article-id pub-id-type="pmcaid">10295010</article-id><article-id pub-id-type="pmcaiid">10295010</article-id><article-id pub-id-type="pmid">37366656</article-id><article-id pub-id-type="doi">10.3390/antib12020041</article-id><article-id pub-id-type="publisher-id">antibodies-12-00041</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent Trends in Active and Passive Immunotherapies of Alzheimer&#8217;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0396-8653</contrib-id><name name-style="western"><surname>Alshamrani</surname><given-names initials="M">Meshal</given-names></name></contrib></contrib-group><aff id="af1-antibodies-12-00041">Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia; <email>malshamrani@jazanu.edu.sa</email></aff><pub-date pub-type="epub"><day>19</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><volume>12</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">434136</issue-id><elocation-id>41</elocation-id><history><date date-type="received"><day>29</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>24</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-28 11:25:10.407"><day>28</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the author.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="antibodies-12-00041.pdf"/><abstract><p>In the elderly, a debilitating condition known as dementia, which is a major health concern, is caused by Alzheimer&#8217;s disease (AD). Despite promising advances by researchers, there is currently no way to completely cure this devastating disease. It is illustrated by the deposition of amyloid &#946;-peptide (A&#946;) plaques that are followed by neural dysfunction and cognitive decline. Responses against AD activate an immune system that contributes to and accelerates AD pathogenesis. Potential efforts in the field of pathogenesis have prompted researchers to explore novel therapies such as active and passive vaccines against A&#946; proteins (A&#946; immunotherapy), intravenous immunoglobulin, and tau immunotherapy, as well as targets that include microglia and several cytokines for the treatment of AD. Aims are now underway by experts to begin immunotherapies before the clinical manifestation, which is made possible by improving the sensitivity of biomarkers used for the diagnosis of AD to have better outcome measures. This review provides an overview of approved immunotherapeutic strategies for AD and those currently being investigated in clinical trials. We examine their mechanisms of action and discuss the potential perspectives and challenges associated with immunotherapies for AD.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>amyloid &#946; peptide</kwd><kwd>astrocytes</kwd><kwd>intravenous immunoglobulin</kwd><kwd>microglia</kwd><kwd>tau</kwd></kwd-group><funding-group><award-group><funding-source>Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia</funding-source><award-id>ISP22-22</award-id></award-group><funding-statement>The authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia, for funding this research work through project number ISP22-22.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibodies-12-00041"><title>1. Introduction</title><p>Alzheimer&#8217;s disease (AD) is an age-related neurodegenerative disorder. Clinically, AD is known for progressive memory impairment, deficits in cognitive abilities, and alterations in personality and behavioral traits [<xref rid="B1-antibodies-12-00041" ref-type="bibr">1</xref>]. This deterioration is more prominent in the hippocampal and temporal regions [<xref rid="B2-antibodies-12-00041" ref-type="bibr">2</xref>]. According to a 2017 Alzheimer&#8217;s Association report, approximately 5.5 million Americans are suffering from AD, and it is expected to increase to 13.8 million by mid-century in the US. Currently, the rate of AD development is one in every 66 s, which may reach 33 s by 2050, which will add one million new cases per year to the list. In the decade 2000&#8211;2014, the mortality rate of AD increased to 89%, while prostate cancer, heart disease, and stroke decreased to 9%, 14%, and 21%, respectively. In 2014, AD became the sixth-most deadly disease in the United States, causing 93,541 deaths. Its treatment is extremely expensive. Average AD health care and treatment costs of &gt;$230 billion, which may increase for patients aged &#8805;65 years, were estimated to be $259 billion in 2017 [<xref rid="B3-antibodies-12-00041" ref-type="bibr">3</xref>]. Moreover, most U.S. nationals are getting to the age of 65 or more, which will increase the number of AD and dementia patients. It is projected to increase from 58 million in 2021 to 88 million in 2050, both in number and proportion [<xref rid="B4-antibodies-12-00041" ref-type="bibr">4</xref>].</p><p>AD is divided into two major categories: familial and sporadic. Familial Alzheimer&#8217;s disease (FAD) is a rare early-onset form of Alzheimer&#8217;s disease caused by mutations in three major genes: amyloid precursor protein (APP), presenilin 1, and presenilin 2. On the other hand, sporadic Alzheimer&#8217;s disease (SAD) is the most common cause of dementia and accounts for more than 90% of Alzheimer&#8217;s cases. SAD tends to strike people without a family history of the disease and occurs late in life, after the age of 65. The clinical features of FAD and SAD are similar, and they do not differ in the incidence of risk factors for dementia or MRI or PET features. However, FAD has an early onset before 65 years of age, whereas SAD has a mean age of onset over 70 years. Understanding the genetic and clinical differences between FAD and SAD is essential for developing effective treatments and management strategies for this devastating disease [<xref rid="B5-antibodies-12-00041" ref-type="bibr">5</xref>,<xref rid="B6-antibodies-12-00041" ref-type="bibr">6</xref>]. Patients with mild cognitive impairment are at a higher risk of developing AD and are sometimes considered to be in an early stage of AD [<xref rid="B7-antibodies-12-00041" ref-type="bibr">7</xref>].</p><p>Presently, the actual cause of AD is unknown, so no efficient disease-modifying therapies are available. Even though many pharmacological strategies are used to delay the progression of cognitive impairment and memory loss, to fight this disease, it is essential to discover novel therapeutic targets [<xref rid="B8-antibodies-12-00041" ref-type="bibr">8</xref>,<xref rid="B9-antibodies-12-00041" ref-type="bibr">9</xref>]. Thus, this improved immune-related insight will deliver attractive biomarkers and novel therapeutic targets for the diagnosis and monitoring of AD [<xref rid="B10-antibodies-12-00041" ref-type="bibr">10</xref>,<xref rid="B11-antibodies-12-00041" ref-type="bibr">11</xref>,<xref rid="B12-antibodies-12-00041" ref-type="bibr">12</xref>]. A&#946; immunotherapy results in plaque elimination and functional benefit. Numerous successive clinical trials that include both active (AN1792) and passive immunization (e.g., Bapineuzumab and Solanezumab) have been verified by autopsy neuropathology and in vivo imaging, which shows that A&#946; from the human brain can be eliminated. However, until now, the evidence for unequivocal cognitive benefits has been slightly unsatisfactory [<xref rid="B8-antibodies-12-00041" ref-type="bibr">8</xref>]. This review provides an overview of approved immunotherapeutic strategies for AD and those currently being investigated in clinical trials. We examine their mechanisms of action and discuss the potential perspectives and challenges associated with immunotherapies for AD.</p></sec><sec id="sec2-antibodies-12-00041"><title>2. Etiopathophysiology of AD</title><p>Usually, AD is illustrated by the extracellular accumulation of &#946;-amyloid (A&#946;) and intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylation of the tau protein that leads to synaptic dysfunction and neuronal death [<xref rid="B5-antibodies-12-00041" ref-type="bibr">5</xref>,<xref rid="B13-antibodies-12-00041" ref-type="bibr">13</xref>]. The &#8220;amyloid cascade hypothesis&#8221;, a longstanding hypothesis that has a major role in AD, is proposed by Hardy and Higgins [<xref rid="B14-antibodies-12-00041" ref-type="bibr">14</xref>], which suggests that the APP by proteolytic cleavage results in the accumulation of insoluble A&#946; fragments that is the key stimulus in driving AD pathology. While the imbalanced A&#946; production and clearance result in further disease progression, including NFT formation (<xref rid="antibodies-12-00041-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B15-antibodies-12-00041" ref-type="bibr">15</xref>].</p><p>An amyloid plaque contains A&#946; 1&#8211;42 peptide, i.e., a derivative of membrane-stacked APP, which is the main component that gets organized into dense fibrils and intermingles with non-fibrillar peptide. Plaques also hold deteriorating axons and dendrites, and these are encircled by reactive astrocytes and some microglia [<xref rid="B16-antibodies-12-00041" ref-type="bibr">16</xref>]. NFTs comprise tau proteins associated with microtubules that are generally expressed in axons. However, in AD pathogenesis, hyperphosphorylation of tau leads to the aggregation of abnormal filaments in the cell body, thus impairing the regular activity of tau in the polymerization and stabilization of tubulin. This hyperphosphorylation of tau is performed by mitogen-activated protein kinases (MAPK) due to the overexpression of MAPK/ERKs in an AD brain [<xref rid="B16-antibodies-12-00041" ref-type="bibr">16</xref>].</p><p>The inflammatory response in AD pathology is chiefly driven by microglia and intensifies with disease progression, which indicates the role of the immune system in AD; however, the significance of inflammation in AD pathogenesis is well appreciated and considered to contribute to and exacerbate AD [<xref rid="B10-antibodies-12-00041" ref-type="bibr">10</xref>,<xref rid="B17-antibodies-12-00041" ref-type="bibr">17</xref>].</p><p>AD is characterized by two distinct pathological features: extracellular deposits of beta-amyloid in neuritic plaques and intracellular neurofibrillary tangles composed of paired helical filaments. These abnormalities result in synaptic and neuronal loss, leading to noticeable brain atrophy, particularly in the mesial temporal lobe [<xref rid="B18-antibodies-12-00041" ref-type="bibr">18</xref>,<xref rid="B19-antibodies-12-00041" ref-type="bibr">19</xref>].</p><p>The precise mechanisms by which beta-amyloid and neurofibrillary tangles cause damage in AD are not yet fully understood, giving rise to several proposed theories. The amyloid hypothesis suggests that the progressive buildup of beta-amyloid triggers a complex cascade of events that ultimately culminate in neuronal cell death, synapse loss, and neurotransmitter deficits, contributing to the clinical symptoms of dementia [<xref rid="B20-antibodies-12-00041" ref-type="bibr">20</xref>,<xref rid="B21-antibodies-12-00041" ref-type="bibr">21</xref>].</p><p>Inflammation and immune responses have emerged as significant contributors to AD pathology, potentially representing a third core pathological feature. Disturbances in glucose metabolism have also been implicated in the development of AD [<xref rid="B22-antibodies-12-00041" ref-type="bibr">22</xref>,<xref rid="B23-antibodies-12-00041" ref-type="bibr">23</xref>].</p><p>AD shares similarities with prion diseases, as beta-amyloid and tau proteins exhibit prion-like properties. These proteins can self-replicate and contribute to disease progression by inducing misfolding in their normal counterparts, leading to abnormal accumulation and subsequent brain damage. Further research is necessary to fully comprehend the intricacies of these mechanisms and their implications for AD pathogenesis [<xref rid="B24-antibodies-12-00041" ref-type="bibr">24</xref>,<xref rid="B25-antibodies-12-00041" ref-type="bibr">25</xref>,<xref rid="B26-antibodies-12-00041" ref-type="bibr">26</xref>,<xref rid="B27-antibodies-12-00041" ref-type="bibr">27</xref>].</p></sec><sec id="sec3-antibodies-12-00041"><title>3. Involvement of the Immune System and Inflammation in AD</title><p>Recent bioinformatics, genetic, and preclinical data highlight that neuroinflammation mediated by immune activation exacerbates and contributes to AD pathogenesis [<xref rid="B28-antibodies-12-00041" ref-type="bibr">28</xref>]. Immense anomalous interactions have been found among A&#946;, neurons, astrocytes, and microglia of the central nervous system (CNS) in the proteinopathy AD of the elderly that employ a malicious cycle in AD immune-neuropathology [<xref rid="B29-antibodies-12-00041" ref-type="bibr">29</xref>]. These multicellular interactions occur due to the accumulation of cytotoxic proteins (insoluble NFTs and A&#946; plaques) in definite regions of the brain. Insoluble NFTs and A&#946; plaques are crucial factors in AD pathogenesis by forming senile plaques in the brain [<xref rid="B30-antibodies-12-00041" ref-type="bibr">30</xref>,<xref rid="B31-antibodies-12-00041" ref-type="bibr">31</xref>]. Due to proteinopathy, these neuronal cells initiate the recruitment, immigration, and aggregation of astrocytes and microglia near affected neurons. Microglia are the mononuclear phagocytes that normally act as the protective cells of the CNS, while astrocytes are the supporters of neuron cells that supply nutrients and maintain pH by accumulating at synapses. Damaged neurons initially attract microglia by secreting fractalkine (CX3CL1), which acts on the microglial receptor CX3CR1, as well as an astrocyte-released glial-derived neurotrophic factor (GDNF), which interacts with the GDNF receptor [<xref rid="B32-antibodies-12-00041" ref-type="bibr">32</xref>,<xref rid="B33-antibodies-12-00041" ref-type="bibr">33</xref>,<xref rid="B34-antibodies-12-00041" ref-type="bibr">34</xref>,<xref rid="B35-antibodies-12-00041" ref-type="bibr">35</xref>].</p><p>Neuronal oligomeric A&#946;42 in neurodegenerative lesions directly attracts microglia and, to a lesser extent, astrocytes through a wide range of receptors, most prominently TLRs 4, TRLs 6, and CD36 [<xref rid="B34-antibodies-12-00041" ref-type="bibr">34</xref>,<xref rid="B36-antibodies-12-00041" ref-type="bibr">36</xref>,<xref rid="B37-antibodies-12-00041" ref-type="bibr">37</xref>]. Astrocytes are also attracted to the neurodegenerative lesion by CC chemokine ligand 2 (CCL2) and monocyte chemoattractant protein-1 secreted by activated astrocytes, neurons, and particularly activated microglia [<xref rid="B33-antibodies-12-00041" ref-type="bibr">33</xref>]. Blood monocytes are also drawn to such lesions through CCL2 and CC chemokine receptor (CCR2) interactions, which then differentiate to form more potent macrophages than senescent microglia and exacerbate the ongoing pathogenesis by promoting inflammation [<xref rid="B38-antibodies-12-00041" ref-type="bibr">38</xref>,<xref rid="B39-antibodies-12-00041" ref-type="bibr">39</xref>]. Increased accumulation of neuronal cells (astrocytes, microglia) around the damaged neuron (induced directly or indirectly (through cytokines) by neurotoxic proteins) leads to multicellular interactions that cause further activation of cells and elicit more pathogenic alterations. IL-34 secretion by neurons and sometimes by T cells and dendritic cells increases microglial survival, proliferation, and function (cytokine production) by acting on the colony-stimulating factor-1 receptor [<xref rid="B34-antibodies-12-00041" ref-type="bibr">34</xref>,<xref rid="B40-antibodies-12-00041" ref-type="bibr">40</xref>].</p><p>Microglial-derived cytokines work in combinations (TNF-&#945; and IFN-r or IL-1&#946; and IFN-r) to stimulate astrocyte proliferation and enhance the production of the precursors of the amyloidogenic pathway that include APP and &#946;-site APP cleaving enzyme 1 (BACE-1) that are delivered efficiently by astrocyte-derived exosomes (ADE) to neurons and stimulate abnormally elevated A&#946;42 production [<xref rid="B41-antibodies-12-00041" ref-type="bibr">41</xref>,<xref rid="B42-antibodies-12-00041" ref-type="bibr">42</xref>,<xref rid="B43-antibodies-12-00041" ref-type="bibr">43</xref>]. At that stage, activated cells are fully equipped to attain peak neuronal destruction through diverse mechanisms such as complement-mediated lysis, cytokine-induced damage, pruning of neurons by phagocytosis, and mitochondrial transfer [<xref rid="B44-antibodies-12-00041" ref-type="bibr">44</xref>].</p><p>In chronic neurodegenerative lesions, neuronal, astrocytic, and microglial effects undergo alteration, resulting in increased product secretions and prolonged destructive effects on other cell types. In AD, increased secretion of cytokines by inflammatory microglia further promotes astrocyte production and activation, which in turn increases the secretion of chemokines (CXCL10, CCL3, and CCL5) that further activate microglia [<xref rid="B44-antibodies-12-00041" ref-type="bibr">44</xref>]. GDNF levels, either from activated astrocytes or inflammatory-type microglia that normally enhance synaptic function, neuronal survival, or plasticity, may be elevated or diminished in AD depending upon the disease stage [<xref rid="B43-antibodies-12-00041" ref-type="bibr">43</xref>,<xref rid="B45-antibodies-12-00041" ref-type="bibr">45</xref>,<xref rid="B46-antibodies-12-00041" ref-type="bibr">46</xref>].</p><p>Activated astrocytes (particularly under ischemic conditions) are capable of transferring mitochondria into the neurons to increase or decrease neuronal survival, but this role is still under analysis for AD [<xref rid="B47-antibodies-12-00041" ref-type="bibr">47</xref>]. Activated microglia that become rich in A&#946; plaques enhance the inflammatory response by stimulating NF&#954;B (a nuclear factor) and by regulating the MAPK pathway and extracellular signal-regulated kinase that is involved in cytokines and chemokines production [<xref rid="B48-antibodies-12-00041" ref-type="bibr">48</xref>,<xref rid="B49-antibodies-12-00041" ref-type="bibr">49</xref>]. These molecules, in conjugation with free radicals and complement components, intensify neuronal dysfunction, which eventually leads to death [<xref rid="B50-antibodies-12-00041" ref-type="bibr">50</xref>].</p><p>Inflammatory responses can also be driven by both CNS intrinsic and extrinsic factors (systemic influence). Intrinsic conditions (e.g., locus coeruleus degeneration, traumatic brain injury) and extrinsic conditions (type 2 diabetes, obesity, and systemic inflammation due to chronic disorders) are involved in neuroinflammation and microglia activation that facilitate AD pathogenesis [<xref rid="B51-antibodies-12-00041" ref-type="bibr">51</xref>,<xref rid="B52-antibodies-12-00041" ref-type="bibr">52</xref>,<xref rid="B53-antibodies-12-00041" ref-type="bibr">53</xref>,<xref rid="B54-antibodies-12-00041" ref-type="bibr">54</xref>,<xref rid="B55-antibodies-12-00041" ref-type="bibr">55</xref>].</p><p>Recently, the relationship between genes of innate immunity and AD pathogenesis has been found in sporadic AD by genome-wide association studies, as shown by AD-associated mutations in myeloid genes that encode triggering receptors expressed on myeloid cells 2, CD33, a surface antigen, and complement receptor 1 (CR1) [<xref rid="B56-antibodies-12-00041" ref-type="bibr">56</xref>,<xref rid="B57-antibodies-12-00041" ref-type="bibr">57</xref>,<xref rid="B58-antibodies-12-00041" ref-type="bibr">58</xref>,<xref rid="B59-antibodies-12-00041" ref-type="bibr">59</xref>].</p></sec><sec id="sec4-antibodies-12-00041"><title>4. Diagnoses</title><p>A well-known pathological hallmark of AD is A&#946; peptides and NFTs comprised of phosphorylated tau (p-tau) [<xref rid="B60-antibodies-12-00041" ref-type="bibr">60</xref>]. An analysis by Rajan et al. has revealed that cognition and memory impairment initiate about 18 years before clinical diagnoses of AD [<xref rid="B61-antibodies-12-00041" ref-type="bibr">61</xref>]. Thus, AD cannot be diagnosed at an early stage, and when the symptoms appear and AD is clinically diagnosed, then neurodegeneration has already reached significantly advanced stages with marked neural and synaptic dysfunction [<xref rid="B62-antibodies-12-00041" ref-type="bibr">62</xref>]. Late clinical diagnosis is a consequence of nonspecific diagnostic tests. Early AD diagnosis is often subjective and determined by GPs (usually neurologists, psychiatrists, and geriatricians) and depends upon their experience [<xref rid="B63-antibodies-12-00041" ref-type="bibr">63</xref>].</p><p>The rising incidence of AD and neurodegenerative pathogenesis demands the urgent development of reliable biomarkers that can be identified at the preclinical stage for precise diagnosis and efficient monitoring of the disease [<xref rid="B64-antibodies-12-00041" ref-type="bibr">64</xref>]. Recently, intensified efforts have been made to develop such AD biomarkers that can be detected in cerebrospinal fluid (CSF), blood, and brain imaging [<xref rid="B65-antibodies-12-00041" ref-type="bibr">65</xref>,<xref rid="B66-antibodies-12-00041" ref-type="bibr">66</xref>]. Here, CSF biomarkers are the most important as they depict diseased-brain neuropathology [<xref rid="B64-antibodies-12-00041" ref-type="bibr">64</xref>]. For AD, the major CSF biomarkers are A&#946;42, p-tau, and total-tau (t-tau). Apart from CSF biomarkers, plasma t-tau and neurofilament light protein (NFL) are also associated with AD [<xref rid="B67-antibodies-12-00041" ref-type="bibr">67</xref>]. CSF protein profiles provide a better understanding of brain pathological changes. AD and mild cognitive impairment patients have an elevated level of CSF p-tau (Thr 181) and t-tau, while the declined level of CSF A&#946;42 reflects plaque pathology [<xref rid="B68-antibodies-12-00041" ref-type="bibr">68</xref>,<xref rid="B69-antibodies-12-00041" ref-type="bibr">69</xref>,<xref rid="B70-antibodies-12-00041" ref-type="bibr">70</xref>]. In the CSF, FAD mutation carriers (APP, Presenilin-1) also have elevated total and p-tau (Thr 181) levels, which is a sensitive indicator of pre-symptomatic AD [<xref rid="B71-antibodies-12-00041" ref-type="bibr">71</xref>].</p><p>Besides biomarkers, neuroimaging approaches provide a noninvasive and precise assessment of neuronal function [<xref rid="B72-antibodies-12-00041" ref-type="bibr">72</xref>]. The most common efficient techniques include functional magnetic resonance imaging (fMRI), magneto-encephalography (MEG), electroencephalography (EEG), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and functional near-infrared spectroscopy (fNIRS) [<xref rid="B73-antibodies-12-00041" ref-type="bibr">73</xref>]. Computerized diagnostic tools examine the cerebral neurodegeneration pattern from the images to diagnose AD. MRI and PET techniques quantify brain changes and metrics such as white and gray matter, cortical thickness, and hippocampus shape and volume for AD progression. Moreover, 18-Fluoro-DeoxyGlucose PET (FDG-PET) identifies the glucose metabolic rate at cerebral regions that assist in AD diagnosis [<xref rid="B72-antibodies-12-00041" ref-type="bibr">72</xref>].</p></sec><sec id="sec5-antibodies-12-00041"><title>5. Current Treatments for AD</title><p>Currently, no proper medicinal treatment is available for AD that slows or inhibits neuronal destruction; as a consequence, AD symptoms appear, thus making the disease fatal. Hence, the need for efficient treatments has increased greatly to monitor AD progression [<xref rid="B74-antibodies-12-00041" ref-type="bibr">74</xref>]. In the last 30 years, significant developments have been made to understand the genetics, neuropathology, and biochemistry of AD [<xref rid="B9-antibodies-12-00041" ref-type="bibr">9</xref>,<xref rid="B75-antibodies-12-00041" ref-type="bibr">75</xref>]. Unfortunately, only six drugs are approved by the Food and Drug Administration (FDA), USA, for the symptomatic treatment of AD by increasing the concentration of neurotransmitters in the AD brain. These drugs vary in their effectiveness from individual to individual and have a limited duration [<xref rid="B3-antibodies-12-00041" ref-type="bibr">3</xref>,<xref rid="B76-antibodies-12-00041" ref-type="bibr">76</xref>].</p><p>Memantine (a NMDA receptor antagonist) and acetylcholinesterase inhibitors (AChEIs) are currently used for the management of AD symptoms, but these drugs cannot inhibit disease progression due to their limited effectiveness [<xref rid="B77-antibodies-12-00041" ref-type="bibr">77</xref>]. Several disease-modifying drugs were found unsuccessful in clinical trials as they exhibit mechanism-based side effects. These drugs are mainly A&#946;-targeted and comprise &#947;-secretase or &#946;-secretase inhibitors, which prohibit A&#946; production [<xref rid="B75-antibodies-12-00041" ref-type="bibr">75</xref>]. In the 2002&#8211;2012 decade, 244 AD drugs registered by the clinical trials government were tested in clinical trials. Disappointingly, only one out of 244 drugs got approval from the FDA after completing the clinical trials [<xref rid="B3-antibodies-12-00041" ref-type="bibr">3</xref>].</p><p>After the confirmation of inflammation-mediated AD pathogenesis, anti-inflammatory drugs, mainly nonsteroidal anti-inflammatory drugs (NSAIDs), that were thought to protect against AD are tested as a therapeutic option in a clinical trial. However, despite these promises, not even a single drug is involved in slowing the progression of cognitive dysfunction in mild to moderate AD patients. Therefore, NSAIDs as well as other approaches targeting metals, oxidative damage, etc. are no longer used as a viable treatment for AD [<xref rid="B78-antibodies-12-00041" ref-type="bibr">78</xref>,<xref rid="B79-antibodies-12-00041" ref-type="bibr">79</xref>]. Various factors contribute to this difficulty in the development of effective AD treatment, including the high costs of drug development, the fact that only specialized small drug molecules can move across the blood-brain barrier (a protective layer) of the brain, and the lengthy observation period required to investigate the effectiveness of treatment [<xref rid="B3-antibodies-12-00041" ref-type="bibr">3</xref>].</p><p>Recently, the discovery of AD biomarkers and advancements in biomolecular mechanism identification have directed that novel therapies modify early-phase pathogenic mechanisms. As A&#946; deposition is the key incident in AD pathogenesis, numerous therapeutic approaches have been developed that are involved in A&#946; clearance and impede A&#946; production or aggregation. Among these strategies, immunotherapy is the most researched therapeutic approach [<xref rid="B80-antibodies-12-00041" ref-type="bibr">80</xref>]. Srivastava et al. suggested combined therapies for the treatment of AD. Multi-targeted drugs can be used, but no potential drug has been developed beyond phase II/III trials. Still, problems remain with difficulties in crossing the blood-brain barrier, a long serum half-life, and low bioavailability. Researchers are now interested in miRNA replacement therapy for AD treatment with restricted interactions [<xref rid="B1-antibodies-12-00041" ref-type="bibr">1</xref>].</p></sec><sec id="sec6-antibodies-12-00041"><title>6. Immunotherapy and Its Types</title><p>A promising approach for combating AD is amyloid immunotherapy, which includes various anti-A&#946; strategies such as the production of anti-A&#946; antibodies that are being fashioned actively (vaccines) or passively to prevent A&#946; peptide aggregates and lower their production [<xref rid="B81-antibodies-12-00041" ref-type="bibr">81</xref>,<xref rid="B82-antibodies-12-00041" ref-type="bibr">82</xref>]. To excite the immune system in the host that affects the production of anti-A&#946; antibodies, A&#946; active immunization involves the processing of synthetic A&#946; peptide conjugated to a carrier protein, while in passive immunotherapy, there is no requirement to hook up the immune system; instead, A&#946;-specific antibodies are directly injected into the host [<xref rid="B80-antibodies-12-00041" ref-type="bibr">80</xref>,<xref rid="B82-antibodies-12-00041" ref-type="bibr">82</xref>].</p></sec><sec id="sec7-antibodies-12-00041"><title>7. Preclinical Immunotherapy Trials in Animal Models</title><p>APP is the contributory gene liable for the protein, taking account of the A&#946; peptide. In 1980, A&#946; deposits ensured sequencing, and APP was cloned by Glenner. To dissipate A&#946; deposits and prevent monomers from aggregating, experiments were performed in vitro that distort the A&#946; peptides [<xref rid="B83-antibodies-12-00041" ref-type="bibr">83</xref>]. Preclinical immunotherapy for AD in transgenic mice (Tg) showed the ability to reduce or abolish A&#946; pathology by overexpressing a mutant A&#946; precursor protein (A&#946;PP) with A&#946;42; this was first reported in 1999 [<xref rid="B84-antibodies-12-00041" ref-type="bibr">84</xref>]. After this trial, no noticeable lethal activity was spotted. In later studies, similar fallouts were set and completed by using A&#946;42 with the addition of alum adjuvants, which not only precluded Ab plaque but also advanced cognitive functions [<xref rid="B85-antibodies-12-00041" ref-type="bibr">85</xref>,<xref rid="B86-antibodies-12-00041" ref-type="bibr">86</xref>]. Vaccinating the mouse before acquiring pathology abridged levels of cerebral amyloid that were already present in the transgenic mouse and produced high serum antibody titers [<xref rid="B80-antibodies-12-00041" ref-type="bibr">80</xref>]. This observation that memory deficits are treated by exploiting antibodies for the A&#946; peptide has been extensively practiced in these models, demonstrating that even in some cases, an action (instantly) after a short period of treatment is spotted [<xref rid="B87-antibodies-12-00041" ref-type="bibr">87</xref>]. Other than mice, Beagle dogs that had built up a diffused type of A&#946; deposits that also showed memory aberration with age when treated for two years responded to clearance of diffused deposits but did not fix the memory impairments [<xref rid="B88-antibodies-12-00041" ref-type="bibr">88</xref>].</p></sec><sec id="sec8-antibodies-12-00041"><title>8. Contributory Factors behind AD and Mechanisms of Their Clearance</title><p>AD is rooted mainly because of three reasons: A&#946; deposits, &#945;-synuclein (&#945;-syn) accumulation in various brain sections, and the dissemination of tau in a prion-like fashion [<xref rid="B89-antibodies-12-00041" ref-type="bibr">89</xref>,<xref rid="B90-antibodies-12-00041" ref-type="bibr">90</xref>,<xref rid="B91-antibodies-12-00041" ref-type="bibr">91</xref>]. Lethality in AD is also yielded by oligomers&#8217; presence in the brain, imparting deleterious effects such as damage to synaptic function, disturbances in autophagy, and gene transcription [<xref rid="B92-antibodies-12-00041" ref-type="bibr">92</xref>,<xref rid="B93-antibodies-12-00041" ref-type="bibr">93</xref>,<xref rid="B94-antibodies-12-00041" ref-type="bibr">94</xref>]. Recently, it has been stated that there is an intermingling of protein accretion [<xref rid="B95-antibodies-12-00041" ref-type="bibr">95</xref>].</p><p>Three mechanisms have been presented as immunotherapies for AD. Initiation of microglia and macrophages; secondary structure modification of A&#946; monomer; peripheral sink hypothesis, which states that by upsetting the constancy of A&#946; among the plasma and CNS, there is an escalation of the outflow of A&#946; from the brain (<xref rid="antibodies-12-00041-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B96-antibodies-12-00041" ref-type="bibr">96</xref>].</p><sec id="sec8dot1-antibodies-12-00041"><title>8.1. Initiation of Microglia and Macrophages</title><p>In the first proposed mechanism, the opsonization technique is implicated, in which the pathogen is tagged, leading to macrophage phagocytosis and complement activation. The basic principle of this approach presumes that an adequate amount of antibody leads into the brain to regulate inflammation by activating clearance through microglia. This response is possible when these antibodies fasten to the amyloid, and after systemic administration of anti-amyloid antibodies, recovery from amyloid deposits has been demonstrated [<xref rid="B97-antibodies-12-00041" ref-type="bibr">97</xref>,<xref rid="B98-antibodies-12-00041" ref-type="bibr">98</xref>,<xref rid="B99-antibodies-12-00041" ref-type="bibr">99</xref>].</p></sec><sec id="sec8dot2-antibodies-12-00041"><title>8.2. Peripheral Sink Hypothesis</title><p>This hypothesis involves the creation of a &#8220;peripheral sink&#8221;, which leads to the withdrawal of A&#946; from the brain via anti-A&#946; antibodies (A&#946;-specific IgG) [<xref rid="B100-antibodies-12-00041" ref-type="bibr">100</xref>,<xref rid="B101-antibodies-12-00041" ref-type="bibr">101</xref>]. The high affinity for A&#946; of many antibodies does considerably elevate circulating concentrations, and many mechanisms appear there by which entry into the CNS is made by circulating A&#946;; this reduces free A&#946; in the brain [<xref rid="B102-antibodies-12-00041" ref-type="bibr">102</xref>].</p></sec><sec id="sec8dot3-antibodies-12-00041"><title>8.3. A&#946; Oligomers Neutralization by Antibodies</title><p>The presence of soluble aggregates called &#8220;oligomers&#8221; in elevated amounts accounts for AD even if no genetic abnormality is seen in the patients [<xref rid="B103-antibodies-12-00041" ref-type="bibr">103</xref>]. A third approach involves secondary structure modification of A&#946; monomers by using the catalytic characteristics of antibodies. This confirms that oligomers do not amass. Mechanism suggests that the disbanding of amyloid composites occurs through a straightforward effect on A&#946; because here A&#946; antibodies act as chaperones [<xref rid="B83-antibodies-12-00041" ref-type="bibr">83</xref>]. For the blockage of A&#946; fibril formation in vitro, the required stoichiometry of antibodies is as low as 1:10. These outcomes were further extended, which concluded that atomic force microscopy (AFM) indicates that antibodies in a ratio of 1:1000 are needed to obstruct oligomers [<xref rid="B104-antibodies-12-00041" ref-type="bibr">104</xref>].</p></sec></sec><sec id="sec9-antibodies-12-00041"><title>9. Active Immunization (Vaccine) Clinical Trials</title><p>Further, immunohistochemical assays made their way to clinical trials in humans so that immune interventions in humans could also be performed after observing results in mice, which revealed that immunization antibodies hostile to A&#946; can also be beneficial in human AD eradication by acting on brain segments [<xref rid="B86-antibodies-12-00041" ref-type="bibr">86</xref>,<xref rid="B105-antibodies-12-00041" ref-type="bibr">105</xref>,<xref rid="B106-antibodies-12-00041" ref-type="bibr">106</xref>].</p><p>No toxicity was seen in the immunized mice after preclinical trials. In April 2000, firstly, the trial was put into practice that applied the AN1792 (beta-amyloid [Abeta]1-42) vaccine that activated the immune system because of the incidence of adjuvant (Qs21) and pre-amassed [<xref rid="B107-antibodies-12-00041" ref-type="bibr">107</xref>]. In the U.K., the above-described study accomplished and performed accounts for 80 patients having an AD at a stage that is considered to be weak to medium [<xref rid="B108-antibodies-12-00041" ref-type="bibr">108</xref>]. Phase 1 is conducted, and its chief objective is to check the arousal of immune activity upon entry of the vaccine. After testing multiple times, results demonstrated that more than 50% of patients could acquire an increased opposing response to A&#946;. To further escalate the progress of the immune system, an emulsifier, polysorbate 80, is added, which benefits it more [<xref rid="B109-antibodies-12-00041" ref-type="bibr">109</xref>].</p><p>The execution of Phase II in October involved a total of 372 patients, of whom 300 were given a higher dose of vaccine along with emulsifiers in a 4:1 ratio. On receiving such a high dose, symptoms of aseptic meningoencephalitis were exhibited by 6% of immunized patients, and early in January 2002, the trial was completed [<xref rid="B107-antibodies-12-00041" ref-type="bibr">107</xref>,<xref rid="B110-antibodies-12-00041" ref-type="bibr">110</xref>,<xref rid="B111-antibodies-12-00041" ref-type="bibr">111</xref>]. The extent to which symptoms continued is 5&#8211;168 days and includes headache, lethargy, and confusion. Likewise, the data from the animal model and the analysis of a postmortem-evidenced deduction of A&#946; peptide masses endorsed the efficacy of the approach [<xref rid="B111-antibodies-12-00041" ref-type="bibr">111</xref>,<xref rid="B112-antibodies-12-00041" ref-type="bibr">112</xref>,<xref rid="B113-antibodies-12-00041" ref-type="bibr">113</xref>,<xref rid="B114-antibodies-12-00041" ref-type="bibr">114</xref>,<xref rid="B115-antibodies-12-00041" ref-type="bibr">115</xref>]. Plaques have a moth-eaten appearance, or, in other words, naked, dense interiors. Histopathology also revealed that these plaques are associated with microglia and involve phagocytosis for clearance, and it also revealed that tau-related pathology is not targeted [<xref rid="B113-antibodies-12-00041" ref-type="bibr">113</xref>,<xref rid="B114-antibodies-12-00041" ref-type="bibr">114</xref>]. The toxic comeback was marked when further trials were conducted in vitro, in which peripheral mononuclear cells from patients were examined upon triggering by the Ab peptide. Cytokines are produced and quantified by ELISA, which shows the production of interleukins and interferon-gamma by the patient&#8217;s cells; this is generated by CD4<sup>+</sup> receptors of T-helper. Stated that a more worthy result is obtained by applying a high amount of antibody solutions; this information is obtained by following the Zurich cohort results [<xref rid="B109-antibodies-12-00041" ref-type="bibr">109</xref>]. With such a remarkable fall in plaques, the benefits obtained in cognitive function are negligible, while the result in pathology is remarkable [<xref rid="B110-antibodies-12-00041" ref-type="bibr">110</xref>]. Various assessments of active immunotherapy vaccinations are still proceeding worldwide, especially in the USA [<xref rid="B116-antibodies-12-00041" ref-type="bibr">116</xref>,<xref rid="B117-antibodies-12-00041" ref-type="bibr">117</xref>].</p></sec><sec id="sec10-antibodies-12-00041"><title>10. Active Immunotherapy Antibodies</title><p>The first active immunotherapy approach used was AN1792, with promising results of reduced functional decline, but its use was stopped clinically due to meningoencephalitis in the immunized diseased persons [<xref rid="B110-antibodies-12-00041" ref-type="bibr">110</xref>]. This was actually due to the activation of T helper (Th1) cells of the immune system, which in turn stimulate proliferative function.</p><p>CAD106 has recently devised an antibody-right formulation against A&#946; deposits where it impedes the A&#946; peptides [<xref rid="B118-antibodies-12-00041" ref-type="bibr">118</xref>]. The Phase 1 assessment of CAD106 gives insight into the view that many of the patients produced anti-A&#946; IgM immunoglobin and less produced IgG against A&#946; [<xref rid="B119-antibodies-12-00041" ref-type="bibr">119</xref>,<xref rid="B120-antibodies-12-00041" ref-type="bibr">120</xref>].</p><p>ACC-001 is an enduring active Phase II trial that involves a small A&#946; fragment and active saponin adjuvant QS-21 with a carrier protein [<xref rid="B121-antibodies-12-00041" ref-type="bibr">121</xref>]. It persuades such a proficient action that is nontoxic, and its study is still being evaluated at present.</p><p>AFFITOPE AD02, recently renamed AD04, targets T-cell activation to evade the adverse effects of AN1792. Its amino-terminal B cell epitope greatly lowers the A&#946; plaques, and it is clinically proven [<xref rid="B122-antibodies-12-00041" ref-type="bibr">122</xref>]. <xref rid="antibodies-12-00041-t001" ref-type="table">Table 1</xref> represents the active immunotherapy clinical trials: advancements in promising treatments.</p><sec id="sec10dot1-antibodies-12-00041"><title>10.1. Tau Immunotherapy</title><p>Over time, the efforts to develop tau immunotherapy and tau-related neurodegenerative disorders have increased immensely in the past couple of years, maybe to a limited extent, because of the disappointment of A&#946; immunotherapy in inverting cognitive deficiencies in moderate to severe AD [<xref rid="B123-antibodies-12-00041" ref-type="bibr">123</xref>]. Currently, tau-directed treatments are not considered as advanced as other therapies developed for modifying AD. The accomplishment of a tau-directed treatment is difficult because tau protein is intracellular [<xref rid="B124-antibodies-12-00041" ref-type="bibr">124</xref>]. However, various examinations have demonstrated the uptake of antibodies by neurons. Furthermore, the cellular stress and inflammatory changes caused by tau pathology may encourage the uptake of antibodies, principally into damaged neurons, conceivably lessening undesirable symptoms. Antibodies may also inhibit the extracellular spread of tau pathology [<xref rid="B125-antibodies-12-00041" ref-type="bibr">125</xref>,<xref rid="B126-antibodies-12-00041" ref-type="bibr">126</xref>,<xref rid="B127-antibodies-12-00041" ref-type="bibr">127</xref>].</p><p>Up until now, approximately eight preclinical reports have been publicized concerning the useful impacts of active and passive therapy targeted to tau phospho-epitopes or tau aggregates in the tau Tg mouse model [<xref rid="B123-antibodies-12-00041" ref-type="bibr">123</xref>]. In P301S tau transgenic mice, monoclonal antibodies showed diminished microglial activation, blocked the progression of tau seeding activity identified in cerebrum lysates, and enhanced cognitive abilities [<xref rid="B128-antibodies-12-00041" ref-type="bibr">128</xref>]. Moreover, tau immunotherapy has been found to prevent extreme cognitive debilitation through the extensive removal of abnormal tau [<xref rid="B129-antibodies-12-00041" ref-type="bibr">129</xref>]. In another investigation, tau expression is suppressed in transgenic P301L mice, which demonstrates improved memory, although NFTs remain [<xref rid="B130-antibodies-12-00041" ref-type="bibr">130</xref>]. Thus, preclinical studies in different mouse models recommend that tau immunotherapies with phosphorylated peptides decrease tau phosphorylation and NFT load when treatment is initiated earlier or around the beginning of NFT pathology, demonstrating that the clearance of early pathological aggregates may have a therapeutic advantage [<xref rid="B131-antibodies-12-00041" ref-type="bibr">131</xref>,<xref rid="B132-antibodies-12-00041" ref-type="bibr">132</xref>].</p><p>However, the absence of lucidity in regards to which conformer of tau ought to be directed in this manner remains an issue [<xref rid="B133-antibodies-12-00041" ref-type="bibr">133</xref>]. Overall, all these investigations bolster the viability of targeting pathological tau in AD patients.</p></sec><sec id="sec10dot2-antibodies-12-00041"><title>10.2. ACI-35</title><p>ACI-35 (AC Immune, Lausanne, Switzerland) is a liposomal vaccine that contains a synthetic peptide analog (16 amino acids) of the human tau protein sequence from 393 to 408, with phosphorylation at S396 and S404 residues utilizing a similar technique as ACI-24. In tau P301L transgenic mice and wildtype mice, ACI-35 evoked fast and robust polyclonal antibody reactions specific to p-tau [<xref rid="B134-antibodies-12-00041" ref-type="bibr">134</xref>]. The tolerability of the vaccine was also shown by upgraded clinical attributes and the absence of brain inflammation. This data indicates that ACI-35 could be a safe and viable treatment for AD patients.</p></sec><sec id="sec10dot3-antibodies-12-00041"><title>10.3. AADvac1</title><p>It is a KLH-conjugated tau peptide that is administered with Alhydrogel (aluminum hydroxide adjuvant) and is the first clinically developed vaccine that specifically targets misfolded tau proteins. Transgenic mice and rat vaccination by AADvac1 active and passive therapy decreased NF degeneration and mortality as well as improved neurobehavioral deficiencies [<xref rid="B135-antibodies-12-00041" ref-type="bibr">135</xref>]. The AADvac1 active vaccine is still under observation in a randomized, Phase 1, 3-month clinical trial to assess its efficacy, safety, and tolerability in mild-to-moderate AD patients (<uri>ClinicalTrials.gov</uri> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01850238">NCT01850238</ext-link>).</p><table-wrap position="anchor" id="antibodies-12-00041-t001" orientation="portrait"><object-id pub-id-type="pii">antibodies-12-00041-t001_Table 1</object-id><label>Table 1</label><caption><p>Active immunotherapy clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">A&#946; Active Immunotherapy Clinical Trials</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target <break/>(A&#946;/Tau)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trial Phase and Status</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunology</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AN-1792</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELAN (Dublin, Ireland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-A&#946; vaccine <break/>(A&#946; 1&#8211;42 with Qs21 as adjuvant).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; N-terminus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>Halted, no improvement<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00021723">NCT00021723</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction of anti-A&#946; titers by B and T-cell activation. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;CSF tau and no change in CSF A&#946; 42 level.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6% of cases developed Meningoencephalitis and cerebral microhemorrhage</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-antibodies-12-00041" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAD-106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Novartis (Basel, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-A&#946; vaccine <break/>A&#946; 1&#8211;6 peptide along with QB coat protein of bacteriophage. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; N-terminus (AB1-6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>Ongoing<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00956410">NCT00956410</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01023685">NCT01023685</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00795418">NCT00795418</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01097096">NCT01097096</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00733863">NCT00733863</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00411580">NCT00411580</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induction of anti-A&#946; titers without T-cell activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and well-tolerated,<break/>&#8593;&#8593;Total serum A&#946;, &#8595;&#8595;and free A&#946; in plasma while CSF t-tau, p-tau, and A&#946;-40 and 42 remain unchanged.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The occurrence of ARIA in a few cases.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-antibodies-12-00041" ref-type="bibr">137</xref>,<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>,<xref rid="B139-antibodies-12-00041" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACI-24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC immune (Lausanne, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetra-palmitoylated peptide (A&#946; 1&#8211;15) re-formed in liposome.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B sheet conformation of A&#946;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II<break/>Ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02738450">NCT02738450</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The non-inflammatory response of Th2 helper cells against A&#946;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595; insoluble A&#946;40 and 42 and soluble A&#946;42.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant adverse effects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-antibodies-12-00041" ref-type="bibr">117</xref>,<xref rid="B137-antibodies-12-00041" ref-type="bibr">137</xref>,<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACC-001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfizer (New York, NY, USA)/Janssen (Titusville, NJ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-A&#946; vaccine <break/>A&#946; 1&#8211;7/non-toxic diphtheria toxin (CRM197)/Qs21 adjuvant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; 1&#8211;7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>(Completed)<break/>Additional Phase II is ongoing(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01284387">NCT01284387</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00955409">NCT00955409</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01227564">NCT01227564</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00960531">NCT00960531</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01238991">NCT01238991</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00752232">NCT00752232</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00959192">NCT00959192</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00498602">NCT00498602</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00479557">NCT00479557</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces antibody&#8217;s response against A&#946;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and well-tolerated, &#8593;&#8593;plasma A&#946;40, &#8595;&#8595;CSF p-tau slightly, while other CSF biomarkers remain unchanged.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Local injection reactions and headaches; ARIA-E occurs in few cases.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-antibodies-12-00041" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GlaxoSmithKline (Brentford, UK)/AFFiRiS (Vienna, Austria)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; 1&#8211;6 mimetic/keyhole limpet hemocyanin/aluminum adjuvant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mimotope of A&#946; N-terminal </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>Ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01093664">NCT01093664</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01117818">NCT01117818</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02008513">NCT02008513</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00633841">NCT00633841</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00711321">NCT00711321</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01357629">NCT01357629</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01614132">NCT01614132</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00003453">NCT00003453</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00996008">NCT00996008</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulate the immune system to make antibodies against A&#946;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe;<break/>no detailed outcomes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The non-endogenous nature of drugs avoids the development of tolerance.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V-950</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck and Co. (Kenilworth, NJ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; amino-terminal conjugated to ISCO-MATRIX.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I<break/>(Discontinued) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00464334">NCT00464334</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Production of anti-A&#946; antibodies.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results unpublished.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AE&#8217;s rate is high. Mostly Fatigue, nausea, anemia diarrhea,<break/>while in a few cases arrhythmia, dysphagia.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>,<xref rid="B141-antibodies-12-00041" ref-type="bibr">141</xref>]</td></tr><tr><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Tau Active Immunotherapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AADvac1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Axon Neuroscience (Bratislava, Slovakia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-tau vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tau derived peptide<break/>(294&#8211;305 aa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02031198">NCT02031198</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01850238">NCT01850238</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02579252">NCT02579252</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03174886">NCT03174886</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibodies are directed against p-tau and promote tau clearance.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe; <break/>&#8595;&#8595;tau aggregates. <break/>Improved cognition.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant adverse effects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-antibodies-12-00041" ref-type="bibr">135</xref>,<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACI-35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AC immune (Lausanne, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-tau vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tau derived peptide<break/>(294&#8211;305 a.a)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04445831">NCT04445831</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stimulate immune system B and T-cell response. Antibodies are directed against p-tau and promote tau clearance.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;soluble and insoluble tau.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant adverse effects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-antibodies-12-00041" ref-type="bibr">138</xref>,<xref rid="B142-antibodies-12-00041" ref-type="bibr">142</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>&#8593;&#8593; (increase), &#8595;&#8595; (decrease).</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec11-antibodies-12-00041"><title>11. Passive Immunotherapy</title><p>An effective approach that implies the injection of purified, epitope-specific antibodies to target the A&#946; plaques in Alzheimer&#8217;s is passive immunization. The disadvantages of passive immunity, especially in the case of chronic disease, are the need for repeated injections, the selection of proper antigen targets, high costs, the risk of hemorrhages, and the induction of an immune response to the injected antibodies [<xref rid="B86-antibodies-12-00041" ref-type="bibr">86</xref>]. Several preclinical studies were initiated to exploit the ability of passive immunization, which included the treatment of mouse models of AD with A&#946;42 immunotherapy. Results concluded were supportive, as a decline in the A&#946;42 load was perceived, along with the finding that cognitive function is recovering [<xref rid="B143-antibodies-12-00041" ref-type="bibr">143</xref>]. In this study, adverse effects and cerebral microhemorrhages were also noticed [<xref rid="B144-antibodies-12-00041" ref-type="bibr">144</xref>,<xref rid="B145-antibodies-12-00041" ref-type="bibr">145</xref>]. To diminish microhemorrhages, modification of induced antibodies is accomplished with complement proteins and with Fc-g receptors, though with average competence, along with A&#946; deposit reduction. Interestingly, there are several mechanisms to strap up the action of passive immunization by which AD pathology can be facilitated [<xref rid="B86-antibodies-12-00041" ref-type="bibr">86</xref>,<xref rid="B146-antibodies-12-00041" ref-type="bibr">146</xref>].</p><sec id="sec11dot1-antibodies-12-00041"><title>11.1. Antibody Bapineuzumab First-Generation Anti-Fibrillar Forms of A&#946;</title><p>Currently, advances in passive immunotherapy are ongoing, and several trials are under study. Phase III trials in this respect comprise Bapineuzumab and Solanezumab, but when tried clinically, results were not satisfactory [<xref rid="B147-antibodies-12-00041" ref-type="bibr">147</xref>,<xref rid="B148-antibodies-12-00041" ref-type="bibr">148</xref>,<xref rid="B149-antibodies-12-00041" ref-type="bibr">149</xref>]. A humanized depiction targeting A&#946; 1&#8211;5 deposits is an anti-A&#946; monoclonal antibody, which is said to be Bapineuzumab. The fall in levels of CSF A&#946; is significantly noticed in the results of Phase II clinical trials of Bapineuzumab; in addition to that impact, CSF p-tau and t-tau levels also showed a decrease [<xref rid="B150-antibodies-12-00041" ref-type="bibr">150</xref>,<xref rid="B151-antibodies-12-00041" ref-type="bibr">151</xref>,<xref rid="B152-antibodies-12-00041" ref-type="bibr">152</xref>]. To make advancements and seek therapeutic effects underlining safety, several large Phase II and III trials were conducted. In comparison to nanocarriers, the conclusions of Phase II trials that evoked different effects in ApoE4 carriers urged separate Phase III trials. A view by positron emission tomography (PET) in ApoE4 verified that Bapineuzumab has positive effects on brain amyloid with Pittsburg compound B, whereas there are no such impacts in the case of nanoparticles [<xref rid="B153-antibodies-12-00041" ref-type="bibr">153</xref>]. In these trials, noteworthy obstacles were related to amyloid-related imaging abnormalities (ARIA), parenchymal edema (ARIA-E), as well as intracerebral microhemorrhages (ARIA-H) [<xref rid="B147-antibodies-12-00041" ref-type="bibr">147</xref>,<xref rid="B153-antibodies-12-00041" ref-type="bibr">153</xref>]. There are intensified signals on MRI pulse sequences, probably due to leakage of the BBB in ARIA-E. Their reduction attempts were carried out by processing lower doses for apolipoprotein E e4 carriers, but still, several cases were diagnosed, so after all negative clinical outcomes, bapineuzumab has been terminated [<xref rid="B154-antibodies-12-00041" ref-type="bibr">154</xref>].</p></sec><sec id="sec11dot2-antibodies-12-00041"><title>11.2. Antibody Solanezumab First-Generation against Soluble Monomeric Forms of A&#946;</title><p>It is also the first generation, but it is a humanized IgG1 antibody that recognizes the middle sequence in between A&#946; 16&#8211;24. Different properties of solanezumab and bapineuzumab are due to their diversified nature of binding with epitopes; Solanezumab recognizes a central domain epitope, whereas bapineuzumab targets aggregated forms of A&#946;42 in the brain. Such a difference in reports lessened the adverse effects of Solanezumab as compared to Bapineuzumab [<xref rid="B153-antibodies-12-00041" ref-type="bibr">153</xref>,<xref rid="B155-antibodies-12-00041" ref-type="bibr">155</xref>]. In Expedition 1 and Expedition 2, patients with moderate AD were administered in two successive large Phase III trials for 80 weeks, and no adverse effects were reported. This indicated good safety trials, but cognitive function was not improved [<xref rid="B148-antibodies-12-00041" ref-type="bibr">148</xref>]. Later on, studies focusing only on mild AD patients accounted for a decline in cognitive function (33%) [<xref rid="B156-antibodies-12-00041" ref-type="bibr">156</xref>]. Following these results, a large-scale clinical trial (Expedition 3) on mild AD patients was prompted, but it was unsuccessful and showed no cognitive benefits. However, other trials are still ongoing with mild AD patients (Expedition PRO), as depicted on PET imaging by the presence of positive plaques [<xref rid="B157-antibodies-12-00041" ref-type="bibr">157</xref>,<xref rid="B158-antibodies-12-00041" ref-type="bibr">158</xref>].</p><p>Several other second-generation antibodies like AAB-003 (derived from bapineuzumab, Janssen/Pfizer) and GSK933776 that aid in minimizing inflammation and conformational antibodies against A&#946;42 have been proposed and listed in the table that is also being applied clinically (<xref rid="antibodies-12-00041-t002" ref-type="table">Table 2</xref>).</p></sec></sec><sec id="sec12-antibodies-12-00041"><title>12. Intravenous Immunoglobulin (IVIG) Immunotherapy</title><p>IVIG immunotherapy is an alternative approach to passive immunotherapy in which intravenous immunoglobulin (IVIG) is administered, which is a polyclonal antibody mixture obtained from the blood plasma of thousands of young and healthy volunteers [<xref rid="B177-antibodies-12-00041" ref-type="bibr">177</xref>]. It is an FDA-approved drug already being used for the treatment of various cancers, immunodeficiency syndromes, and neurological and inflammatory disorders [<xref rid="B178-antibodies-12-00041" ref-type="bibr">178</xref>]. An investigation concentrating on the potential treatment of AD started in 2002. It has been demonstrated that IVIG exhibits a low affinity for monomeric Ab proteins and a strong affinity for Ab fibrils and neurotoxic oligomers [<xref rid="B179-antibodies-12-00041" ref-type="bibr">179</xref>]. Dodel et al. described that the monthly administration of IVIG to five AD patients reduced CSF A&#223;, increased serum A&#223;, and enhanced cognitive functions [<xref rid="B180-antibodies-12-00041" ref-type="bibr">180</xref>].</p><p>Also, IVIG showed inflammatory and potent immune-modulating effects, vital for the potential treatment of AD. Preliminary clinical investigations revealed decreased cognitive decline. Phase II and III clinical trials have proceeded with IVIG administration in AD patients [<xref rid="B181-antibodies-12-00041" ref-type="bibr">181</xref>]. Generally, three Phases II/III clinical trials: Gammagard, Gamunex, and Octagam 10% were organized on IVIG therapy. A 10% IVIG Gammagard was tested in Phase III trials conducted by Baxter Healthcare Corporation in November 2012 in the US, enrolling 390 patients with mild to moderate AD for almost 18 months [<xref rid="B86-antibodies-12-00041" ref-type="bibr">86</xref>]. Unfortunately, the failure of positive outcomes leads to the termination of the IVIG program for AD (<xref rid="antibodies-12-00041-t003" ref-type="table">Table 3</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00818662">NCT00818662</ext-link>) [<xref rid="B97-antibodies-12-00041" ref-type="bibr">97</xref>,<xref rid="B182-antibodies-12-00041" ref-type="bibr">182</xref>,<xref rid="B183-antibodies-12-00041" ref-type="bibr">183</xref>].</p><p>Presently, games (one of the IVIG products) are actively tested in Phase II/III trials with the enrollment of 350 mild to moderate AD patients (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01561053">NCT01561053</ext-link>). Recently, Octagam IVIG 10% has been observed in two Phase II trials. At first, a placebo-controlled, multicenter Phase II trial was conducted at five sites in Germany and seven in the USA [<xref rid="B186-antibodies-12-00041" ref-type="bibr">186</xref>]. This trial lost its preliminary endpoint of alteration in plasma A&#946; levels and was found negative for most of its secondary biomarker results. While a second, single-centered Phase II trial reported possible effects on brain atrophy as seen by MRI and the Clinical Dementia Rating Sum of Box. The study is still dynamic, but it is not selecting new patients [<xref rid="B187-antibodies-12-00041" ref-type="bibr">187</xref>].</p><p>Generally, IVIG treatment was safe and well tolerated by the patients, even with multiple successive doses. Patients receiving regular infusions of IVIg have markedly decreased their risk of developing dementia [<xref rid="B181-antibodies-12-00041" ref-type="bibr">181</xref>,<xref rid="B188-antibodies-12-00041" ref-type="bibr">188</xref>]. Some positive outcomes have been observed in subgroups, particularly among APOE-e4 bearers and moderate AD patients. Due to the promising results of the initial studies, further trials, including IVIG, are being arranged, and currently enrollment is ongoing for more Phase III clinical trials (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</uri> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01561053">NCT01561053</ext-link>, accessed on 29 March 2023). It also demonstrates anti-inflammatory activity that dramatically increases circulating IgG and results in the regulation of various immune processes by a feedback mechanism until the level returns to normal. Therefore, IVIG can be suggested as an alternative treatment for AD.</p></sec><sec id="sec13-antibodies-12-00041"><title>13. Future Research and Limitations</title><p>Immunotherapy for AD remains a complex and unresolved area of research, necessitating further investigation into the mechanisms of antibody action and factors governing CNS antibody exposure. Passive immunotherapies offer a relatively safe option with enhanced target engagement, although their high cost makes them less viable for long-term public health solutions. Alternatively, the development of effective and safe vaccines holds promise as a cost-effective strategy for addressing the AD epidemic. Successful advancements in AD immunotherapy may revolutionize the treatment landscape for CNS disorders, extending the application of antibodies and vaccines to neurodegenerative, neurological, and psychiatric conditions.</p><p>Significant progress has been made in the non-invasive identification of AD, negating the need for autopsies. Positron emission tomography (PET) using amyloid binding ligands, including Pittsburgh compound B, allows for accurate differentiation of Alzheimer&#8217;s cases from other disorders. Ongoing research on ligands labeled with longer-lived isotopes, such as [18F], expands the possibilities of PET scans by eliminating the requirement for specialized facilities. Studies have demonstrated a reasonable correlation between PET ligand signals and amyloid deposition in the brain. Remarkably, some cognitively normal individuals exhibit positive PET amyloid ligand signals, and longitudinal analysis confirms their predictive value in anticipating the conversion to dementia. Additionally, cerebrospinal fluid analyses can identify individuals with amyloid deposits, even in the absence of dementia symptoms. This opens up avenues for identifying individuals at heightened risk of developing dementia and intervening early to reduce amyloid levels, potentially delaying or preventing the onset of AD.</p><p>Screening high-risk populations through PET scans and cerebrospinal fluid analyses to detect amyloid signatures could facilitate the identification of individuals with amyloid deposits before significant neural damage occurs. Early intervention targeting amyloid reduction holds promise for slowing down or even preventing the development of Alzheimer&#8217;s dementia. Promising results have been observed in the Phase 3 bapineuzumab trial, where PET scans revealed a significant reduction in amyloid signals following 18 months of antibody treatment compared to placebo. Despite challenges like vasogenic edema, other immunotherapy approaches in clinical or preclinical stages offer the potential for reducing amyloid levels before symptom onset, thereby mitigating the cognitive impairments associated with AD. This breakthrough suggests the possibility of preventive measures for high-risk individuals to avert the occurrence of AD.</p></sec><sec sec-type="conclusions" id="sec14-antibodies-12-00041"><title>14. Conclusions</title><p>Broad-based treatments aim to decimate A&#946;42 as it is the key target for causing devastating AD, which includes active immunization and passive immunization. It is an easy mark to target because A&#946;42 does not play any physiological role, so it is considered a superfluous fragment like any pathogen. Other than A&#946;, the reason for AD is tau protein misfolding and aggregation resulting in neurofibrillary meshes, and &#945;-syn is seen amassed in AD-associated plaque formation. Thus, tau-directed immunotherapies are also in progress and are continuing to remove the leading causes of AD. Anti-tau immunotherapy involving antibodies against misfolded tau proteins and their inclusion mediated by receptors aids in the liberation of AD. The ultimate cure is provided by the exploitation of active immunotherapy, which is still associated with a range of adverse effects as the body&#8217;s defense system is unrestrainedly activated. Of the several perilous effects, the major one is amyloid-related imaging abnormality (ARIA). Both therapies offer AD treatment, but only to a limited extent. Likewise, active therapy and passive immunization also impact the body negatively due to the diversified nature of antibodies, but it is still better for their character that antibody management at any time is clogged. Despite potential harms associated with these immunotherapies, there is still hope that the early onset of AD with the administration of an accurately adjusted dose of antibodies against A&#946; could also diminish tau and &#945;-syn. Recent studies in mice are indicative that tau epitopes are very toxic and are not only one in number; this is a prospect for cognitive benefits. Depicted antibodies generate such responses during medication, which could be used as biomarkers for AD that help in its early diagnosis. To gain improved and more beneficial effects indicative of future success, combinatorial therapeutics are needed that target more advanced markers of AD for efficient AD treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Available on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><p>Alzheimer&#8217;s disease: AD, amyloid &#946;-peptide: A&#946;, sporadic Alzheimer&#8217;s disease: SAD, familial Alzheimer&#8217;s disease: FAD, amyloid precursor protein: APP, central nervous system: CNS, neurofibrillary tangles: NFTs, mitogen-activated protein kinases: MAPK, glial-derived neurotrophic factor: GDNF, triggering receptor expressed on myeloid cells 2: TREM2, complement receptor 1: CR1, beta-amyloid [Abeta]1-42: AN1792, phosphorylated tau: p-tau, general physician: GP, cerebrospinal fluid: CSF, total-tau: t-tau, neurofilament light protein: NFL, functional magnetic resonance imaging: fMRI, magneto-encephalography: MEG, electroencephalography: EEG, single-photon emission computed tomography: SPECT, positron emission tomography: PET, functional near-infrared spectroscopy: fNIRS, Food and Drug Administration: FDA, acetylcholinesterase inhibitors: AChEIs, nonsteroidal anti-inflammatory drugs: NSAIDs, atomic force microscopy: AFM, amyloid related imaging abnormalities: ARIA, intravenous immunoglobulin: IVIG.</p></glossary><ref-list><title>References</title><ref id="B1-antibodies-12-00041"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S.K.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease and its treatment by different approaches: A review</article-title><source>Eur. J. Med. Chem.</source><year>2021</year><volume>216</volume><fpage>113320</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113320</pub-id><pub-id pub-id-type="pmid">33652356</pub-id></element-citation></ref><ref id="B2-antibodies-12-00041"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vecchio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Miraglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Piludu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Granata</surname><given-names>G.</given-names></name><name name-style="western"><surname>Romanello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Caulo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Onofrj</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bramanti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colosimo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>P.M.</given-names></name></person-group><article-title>&#8220;Small World&#8221; architecture in brain connectivity and hippocampal volume in Alzheimer&#8217;s disease: A study via graph theory from EEG data</article-title><source>Brain Imaging Behav.</source><year>2017</year><volume>11</volume><fpage>473</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s11682-016-9528-3</pub-id><pub-id pub-id-type="pmid">26960946</pub-id></element-citation></ref><ref id="B3-antibodies-12-00041"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Association</surname><given-names>A.</given-names></name></person-group><article-title>2017 Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement.</source><year>2017</year><volume>13</volume><fpage>325</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.02.001</pub-id></element-citation></ref><ref id="B4-antibodies-12-00041"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Association</surname><given-names>A.</given-names></name></person-group><article-title>2021 Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement.</source><year>2021</year><volume>17</volume><fpage>327</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1002/alz.12328</pub-id><pub-id pub-id-type="pmid">33756057</pub-id></element-citation></ref><ref id="B5-antibodies-12-00041"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Palma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bustos</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Villam&#225;n</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Alarc&#243;n</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Avila</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ugarte</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Opazo</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Ferrari</surname><given-names>G.V.</given-names></name></person-group><article-title>Overrepresentation of glutamate signaling in Alzheimer&#8217;s disease: Network-based pathway enrichment using meta-analysis of genome-wide association studies</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e95413</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095413</pub-id><pub-id pub-id-type="pmid">24755620</pub-id><pub-id pub-id-type="pmcid">PMC3995778</pub-id></element-citation></ref><ref id="B6-antibodies-12-00041"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monjazeb</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glabe</surname><given-names>C.G.</given-names></name></person-group><article-title>Familial Alzheimer&#8217;s disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-&#946; peptide</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>3172</fpage><lpage>3185</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.755264</pub-id><pub-id pub-id-type="pmid">28049728</pub-id><pub-id pub-id-type="pmcid">PMC5336154</pub-id></element-citation></ref><ref id="B7-antibodies-12-00041"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ousset</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Touchon</surname><given-names>J.</given-names></name></person-group><article-title>Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer&#8217;s Disease</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2006</year><volume>77</volume><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2005.085332</pub-id><pub-id pub-id-type="pmid">16549412</pub-id><pub-id pub-id-type="pmcid">PMC2077456</pub-id></element-citation></ref><ref id="B8-antibodies-12-00041"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carare</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Love</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name></person-group><article-title>A&#946; immunotherapy for Alzheimer&#8217;s disease: Effects on apoE and cerebral vasculopathy</article-title><source>Acta Neuropathol.</source><year>2014</year><volume>128</volume><fpage>777</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1007/s00401-014-1340-9</pub-id><pub-id pub-id-type="pmid">25195061</pub-id></element-citation></ref><ref id="B9-antibodies-12-00041"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Alzheimer Disease: An Update on Pathobiology and Treatment Strategies</article-title><source>Cell</source><year>2019</year><volume>179</volume><fpage>312</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></element-citation></ref><ref id="B10-antibodies-12-00041"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>F.L.</given-names></name></person-group><article-title>Microglia as Dynamic and Essential Components of the Amyloid Hypothesis</article-title><source>Neuron</source><year>2013</year><volume>78</volume><fpage>575</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.05.007</pub-id><pub-id pub-id-type="pmid">23719156</pub-id><pub-id pub-id-type="pmcid">PMC6494439</pub-id></element-citation></ref><ref id="B11-antibodies-12-00041"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name></person-group><article-title>Innate immune activation in neurodegenerative disease</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1038/nri3705</pub-id><pub-id pub-id-type="pmid">24962261</pub-id></element-citation></ref><ref id="B12-antibodies-12-00041"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name></person-group><article-title>Microglial priming in neurodegenerative disease</article-title><source>Nat. Rev. Neurol.</source><year>2014</year><volume>10</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.38</pub-id><pub-id pub-id-type="pmid">24638131</pub-id></element-citation></ref><ref id="B13-antibodies-12-00041"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#8217;s disease</article-title><source>Mol. Neurodegener.</source><year>2020</year><volume>15</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s13024-020-00391-7</pub-id><pub-id pub-id-type="pmid">32677986</pub-id><pub-id pub-id-type="pmcid">PMC7364557</pub-id></element-citation></ref><ref id="B14-antibodies-12-00041"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>G.A.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: The amyloid cascade hypothesis</article-title><source>Science</source><year>1992</year><volume>256</volume><fpage>184</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></element-citation></ref><ref id="B15-antibodies-12-00041"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#8217;s disease: Progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="B16-antibodies-12-00041"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angulo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Casad&#243;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mallol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canela</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Vi&#241;als</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lluis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name></person-group><article-title>A1 Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation</article-title><source>Brain Pathol.</source><year>2003</year><volume>13</volume><fpage>440</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2003.tb00475.x</pub-id><pub-id pub-id-type="pmid">14655750</pub-id><pub-id pub-id-type="pmcid">PMC8095992</pub-id></element-citation></ref><ref id="B17-antibodies-12-00041"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prokop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>F.L.</given-names></name></person-group><article-title>Microglia actions in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol.</source><year>2013</year><volume>126</volume><fpage>461</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1182-x</pub-id><pub-id pub-id-type="pmid">24224195</pub-id></element-citation></ref><ref id="B18-antibodies-12-00041"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deture</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name></person-group><article-title>The neuropathological diagnosis of Alzheimer&#8217;s disease</article-title><source>Mol. Neurodegener.</source><year>2019</year><volume>14</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></element-citation></ref><ref id="B19-antibodies-12-00041"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Interaction between A&#946; and Tau in the Pathogenesis of Alzheimer&#8217;s Disease</article-title><source>Int. J. Biol. Sci.</source><year>2021</year><volume>2021</volume><fpage>2181</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.7150/ijbs.57078</pub-id><pub-id pub-id-type="pmcid">PMC8241728</pub-id><pub-id pub-id-type="pmid">34239348</pub-id></element-citation></ref><ref id="B20-antibodies-12-00041"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Villemagne</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The Amyloid-&#946; Pathway in Alzheimer&#8217;s Disease</article-title><source>Mol. Psychiatry</source><year>2021</year><volume>26</volume><fpage>5481</fpage><lpage>5503</lpage><pub-id pub-id-type="doi">10.1038/s41380-021-01249-0</pub-id><pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></element-citation></ref><ref id="B21-antibodies-12-00041"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.</given-names></name></person-group><article-title>If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?</article-title><source>PLoS Biol.</source><year>2022</year><volume>20</volume><elocation-id>e3001694</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001694</pub-id><pub-id pub-id-type="pmid">35862308</pub-id><pub-id pub-id-type="pmcid">PMC9302755</pub-id></element-citation></ref><ref id="B22-antibodies-12-00041"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorfi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maaser-Hecker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>R.E.</given-names></name></person-group><article-title>The neuroimmune axis of Alzheimer&#8217;s disease</article-title><source>Genome Med.</source><year>2023</year><volume>15</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1186/s13073-023-01155-w</pub-id><pub-id pub-id-type="pmid">36703235</pub-id><pub-id pub-id-type="pmcid">PMC9878767</pub-id></element-citation></ref><ref id="B23-antibodies-12-00041"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinney</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Bemiller</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Murtishaw</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Leisgang</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>B.T.</given-names></name></person-group><article-title>Inflammation as a central mechanism in Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement. Transl. Res. Clin. Interv.</source><year>2018</year><volume>4</volume><fpage>575</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2018.06.014</pub-id><pub-id pub-id-type="pmid">30406177</pub-id><pub-id pub-id-type="pmcid">PMC6214864</pub-id></element-citation></ref><ref id="B24-antibodies-12-00041"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willbold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Strodel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schr&#246;der</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Hoyer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>H.</given-names></name></person-group><article-title>Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>8285</fpage><lpage>8307</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.1c00196</pub-id><pub-id pub-id-type="pmid">34137605</pub-id></element-citation></ref><ref id="B25-antibodies-12-00041"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Gonzalez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>R.</given-names></name><name name-style="western"><surname>Duran-Aniotz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Escobedo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pumarola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C.</given-names></name></person-group><article-title>Aged Cattle Brain Displays Alzheimer&#8217;s Disease-Like Pathology and Promotes Brain Amyloidosis in a Transgenic Animal Model</article-title><source>Front. Aging Neurosci.</source><year>2022</year><volume>13</volume><fpage>963</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2021.815361</pub-id><pub-id pub-id-type="pmid">35173603</pub-id><pub-id pub-id-type="pmcid">PMC8841674</pub-id></element-citation></ref><ref id="B26-antibodies-12-00041"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name></person-group><article-title>The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies</article-title><source>Exp. Mol. Med.</source><year>2020</year><volume>52</volume><fpage>1652</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1038/s12276-020-00513-7</pub-id><pub-id pub-id-type="pmid">33051572</pub-id><pub-id pub-id-type="pmcid">PMC8080625</pub-id></element-citation></ref><ref id="B27-antibodies-12-00041"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>L.C.</given-names></name></person-group><article-title>Prion-like mechanisms in Alzheimer disease</article-title><source>Handbook of Clinical Neurology</source><publisher-name>NIH Public Access</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2018</year><volume>Volume 153</volume><fpage>303</fpage><lpage>319</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-444-63945-5.00016-7</pub-id><pub-id pub-id-type="pmcid">PMC6375694</pub-id><pub-id pub-id-type="pmid">29887142</pub-id></element-citation></ref><ref id="B28-antibodies-12-00041"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.-P.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name></person-group><article-title>Microglial priming in Alzheimer&#8217;s disease</article-title><source>Ann. Transl. Med.</source><year>2018</year><volume>6</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.21037/atm.2018.04.22</pub-id><pub-id pub-id-type="pmid">29951498</pub-id><pub-id pub-id-type="pmcid">PMC5994530</pub-id></element-citation></ref><ref id="B29-antibodies-12-00041"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yaoyao Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ting Lau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cheung Hoi Yu</surname><given-names>A.</given-names></name></person-group><article-title>Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease</article-title><source>Curr. Alzheimer Res.</source><year>2011</year><volume>8</volume><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2174/156720511794604543</pub-id><pub-id pub-id-type="pmid">21143158</pub-id></element-citation></ref><ref id="B30-antibodies-12-00041"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinters</surname><given-names>H.V.</given-names></name></person-group><article-title>Emerging concepts in alzheimer&#8217;s disease</article-title><source>Annu. Rev. Pathol. Mech. Dis.</source><year>2015</year><volume>10</volume><fpage>291</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-020712-163927</pub-id><pub-id pub-id-type="pmid">25387055</pub-id></element-citation></ref><ref id="B31-antibodies-12-00041"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aron</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yankner</surname><given-names>B.A.</given-names></name></person-group><article-title>Neurodegenerative disorders: Neural synchronization in Alzheimer&#8217;s disease</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>207</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/540207a</pub-id><pub-id pub-id-type="pmid">27929001</pub-id></element-citation></ref><ref id="B32-antibodies-12-00041"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ku</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Respondek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matyash</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waiczies</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waiczies</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niendorf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Synowitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>R.</given-names></name><etal/></person-group><article-title>GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis</article-title><source>Acta Neuropathol.</source><year>2013</year><volume>125</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s00401-013-1079-8</pub-id><pub-id pub-id-type="pmid">23344256</pub-id></element-citation></ref><ref id="B33-antibodies-12-00041"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease: Chemokines produced by astrocytes and chemokine receptors</article-title><source>Int. J. Clin. Exp. Pathol.</source><year>2014</year><volume>7</volume><fpage>8342</fpage><lpage>8355</lpage><pub-id pub-id-type="pmid">25674199</pub-id><pub-id pub-id-type="pmcid">PMC4314046</pub-id></element-citation></ref><ref id="B34-antibodies-12-00041"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>El Khoury</surname><given-names>J.</given-names></name><name name-style="western"><surname>Landreth</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Brosseron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vitorica</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></element-citation></ref><ref id="B35-antibodies-12-00041"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Th&#233;riault</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivest</surname><given-names>S.</given-names></name></person-group><article-title>The dynamics of monocytes and microglia in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res. Ther.</source><year>2015</year><volume>7</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s13195-015-0125-2</pub-id><pub-id pub-id-type="pmid">25878730</pub-id><pub-id pub-id-type="pmcid">PMC4397873</pub-id></element-citation></ref><ref id="B36-antibodies-12-00041"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muzikansky</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#243;mez-Isla</surname><given-names>T.</given-names></name><name name-style="western"><surname>Growdon</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Betensky</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Frosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in alzheimer disease</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2013</year><volume>72</volume><fpage>462</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3182933788</pub-id><pub-id pub-id-type="pmid">23656989</pub-id><pub-id pub-id-type="pmcid">PMC3661683</pub-id></element-citation></ref><ref id="B37-antibodies-12-00041"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandenbark</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Offner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matejuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matejuk</surname><given-names>A.</given-names></name></person-group><article-title>Microglia and astrocyte involvement in neurodegeneration and brain cancer</article-title><source>J. Neuroinflamm.</source><year>2021</year><volume>18</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s12974-021-02355-0</pub-id><pub-id pub-id-type="pmid">34949203</pub-id><pub-id pub-id-type="pmcid">PMC8697466</pub-id></element-citation></ref><ref id="B38-antibodies-12-00041"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>J.</given-names></name></person-group><article-title>El Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2012</year><volume>9</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.2174/187152710791011982</pub-id><pub-id pub-id-type="pmcid">PMC3684802</pub-id><pub-id pub-id-type="pmid">20205643</pub-id></element-citation></ref><ref id="B39-antibodies-12-00041"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wieghofer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jord&#227;o</surname><given-names>M.J.C.</given-names></name><name name-style="western"><surname>Prutek</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hagemeyer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Staszewski</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kierdorf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Origin, fate and dynamics of macrophages at central nervous system interfaces</article-title><source>Nat. Immunol.</source><year>2016</year><volume>17</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1038/ni.3423</pub-id><pub-id pub-id-type="pmid">27135602</pub-id><pub-id pub-id-type="pmcid">PMC4968048</pub-id></element-citation></ref><ref id="B40-antibodies-12-00041"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olmos-Alonso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schetters</surname><given-names>S.T.T.</given-names></name><name name-style="western"><surname>Sri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Askew</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mancuso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vargas-Caballero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holscher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Gomez-Nicola</surname><given-names>D.</given-names></name></person-group><article-title>Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#8217;s-like pathology</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>891</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1093/brain/awv379</pub-id><pub-id pub-id-type="pmid">26747862</pub-id><pub-id pub-id-type="pmcid">PMC4766375</pub-id></element-citation></ref><ref id="B41-antibodies-12-00041"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vassar</surname><given-names>R.</given-names></name></person-group><article-title>The contribution of activated astrocytes to A&#946; production: Implications for Alzheimer&#8217;s disease pathogenesis</article-title><source>J. Neuroinflamm.</source><year>2011</year><volume>8</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-8-150</pub-id><pub-id pub-id-type="pmcid">PMC3216000</pub-id><pub-id pub-id-type="pmid">22047170</pub-id></element-citation></ref><ref id="B42-antibodies-12-00041"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turola</surname><given-names>E.</given-names></name><name name-style="western"><surname>Furlan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matteoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verderio</surname><given-names>C.</given-names></name></person-group><article-title>Microglial microvesicle secretion and intercellular signaling</article-title><source>Front. Physiol.</source><year>2012</year><volume>3</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.3389/fphys.2012.00149</pub-id><pub-id pub-id-type="pmid">22661954</pub-id><pub-id pub-id-type="pmcid">PMC3357554</pub-id></element-citation></ref><ref id="B43-antibodies-12-00041"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goetzl</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Mustapic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kapogiannis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eitan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lobach</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Goetzl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B.L.</given-names></name></person-group><article-title>Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer&#8217;s disease</article-title><source>FASEB J.</source><year>2016</year><volume>30</volume><fpage>3853</fpage><lpage>3859</lpage><pub-id pub-id-type="doi">10.1096/fj.201600756R</pub-id><pub-id pub-id-type="pmid">27511944</pub-id><pub-id pub-id-type="pmcid">PMC5067254</pub-id></element-citation></ref><ref id="B44-antibodies-12-00041"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>I.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.U.</given-names></name></person-group><article-title>Human astrocytes: Secretome profiles of cytokines and chemokines</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e92325</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092325</pub-id><pub-id pub-id-type="pmid">24691121</pub-id><pub-id pub-id-type="pmcid">PMC3972155</pub-id></element-citation></ref><ref id="B45-antibodies-12-00041"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>D.</given-names></name></person-group><article-title>Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death</article-title><source>Prog. Neurobiol.</source><year>2015</year><volume>130</volume><fpage>86</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.04.003</pub-id><pub-id pub-id-type="pmid">25930681</pub-id></element-citation></ref><ref id="B46-antibodies-12-00041"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name></person-group><article-title>Brain-Derived Neurotrophic Factor in Alzheimer&#8217;s Disease: Risk, Mechanisms, and Therapy</article-title><source>Mol. Neurobiol.</source><year>2015</year><volume>52</volume><fpage>1477</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1007/s12035-014-8958-4</pub-id><pub-id pub-id-type="pmid">25354497</pub-id></element-citation></ref><ref id="B47-antibodies-12-00041"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Terasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>E.H.</given-names></name></person-group><article-title>Transfer of mitochondria from astrocytes to neurons after stroke</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1038/nature18928</pub-id><pub-id pub-id-type="pmid">27466127</pub-id><pub-id pub-id-type="pmcid">PMC4968589</pub-id></element-citation></ref><ref id="B48-antibodies-12-00041"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combs</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Colleen Karlo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Landreth</surname><given-names>G.E.</given-names></name></person-group><article-title>&#946;-amyloid stimulation of microglia anti monocytes results in TNF&#945;-dependent expression of inducible nitric oxide synthase and neuronal apoptosis</article-title><source>J. Neurosci.</source><year>2001</year><volume>21</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-04-01179.2001</pub-id><pub-id pub-id-type="pmid">11160388</pub-id><pub-id pub-id-type="pmcid">PMC6762255</pub-id></element-citation></ref><ref id="B49-antibodies-12-00041"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Drego</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hakimian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Mechanisms of cell signaling and inflammation in Alzheimer&#8217;s disease</article-title><source>Curr. Drug Targets Inflamm. Allergy</source><year>2005</year><volume>4</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.2174/1568010053586237</pub-id><pub-id pub-id-type="pmid">15853747</pub-id></element-citation></ref><ref id="B50-antibodies-12-00041"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastoris</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dossena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aquilani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guerriero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cuzzoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Venturini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ricevuti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bongiorno</surname><given-names>A.I.</given-names></name></person-group><article-title>Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer&#8217;s disease</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2012</year><volume>25</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1177/039463201202500204</pub-id><pub-id pub-id-type="pmid">22697066</pub-id></element-citation></ref><ref id="B51-antibodies-12-00041"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uchio-Yamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kunieda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kurinami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rakugi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R.</given-names></name></person-group><article-title>Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A&#946; deposition in an Alzheimer mouse model with diabetes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>7036</fpage><lpage>7041</lpage><pub-id pub-id-type="doi">10.1073/pnas.1000645107</pub-id><pub-id pub-id-type="pmid">20231468</pub-id><pub-id pub-id-type="pmcid">PMC2872449</pub-id></element-citation></ref><ref id="B52-antibodies-12-00041"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>V.H.</given-names></name></person-group><article-title>Systemic inflammation and disease progression in Alzheimer disease</article-title><source>Neurology</source><year>2009</year><volume>74</volume><fpage>1157</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b6bb95</pub-id><pub-id pub-id-type="pmid">19738171</pub-id><pub-id pub-id-type="pmcid">PMC2848584</pub-id></element-citation></ref><ref id="B53-antibodies-12-00041"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thaler</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Schur</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Guyenet</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sarruf</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Izgur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Maravilla</surname><given-names>K.R.</given-names></name><etal/></person-group><article-title>Obesity is associated with hypothalamic injury in rodents and humans</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1172/JCI59660</pub-id><pub-id pub-id-type="pmid">22201683</pub-id><pub-id pub-id-type="pmcid">PMC3248304</pub-id></element-citation></ref><ref id="B54-antibodies-12-00041"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalermpalanupap</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rorabaugh</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Liles</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Lah</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Levey</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Weinshenker</surname><given-names>D.</given-names></name></person-group><article-title>Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice</article-title><source>J. Neurosci.</source><year>2018</year><volume>38</volume><fpage>74</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1483-17.2017</pub-id><pub-id pub-id-type="pmid">29133432</pub-id><pub-id pub-id-type="pmcid">PMC5761438</pub-id></element-citation></ref><ref id="B55-antibodies-12-00041"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veitch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.</given-names></name><name name-style="western"><surname>Decarli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer&#8217;s disease in Vietnam Veterans using the Alzheimer&#8217;s Disease Neuroimaging Initiative: Preliminary report</article-title><source>Alzheimers Dement. Transl. Res. Clin. Interv.</source><year>2017</year><volume>3</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.02.005</pub-id><pub-id pub-id-type="pmid">28758146</pub-id><pub-id pub-id-type="pmcid">PMC5526098</pub-id></element-citation></ref><ref id="B56-antibodies-12-00041"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradshaw</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Chibnik</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Keenan</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Ottoboni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosenkrantz</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Imboywa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Von Korff</surname><given-names>A.</given-names></name><etal/></person-group><article-title>CD33 Alzheimer&#8217;s disease locus: Altered monocyte function and amyloid biology</article-title><source>Nat. Neurosci.</source><year>2013</year><volume>16</volume><fpage>848</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/nn.3435</pub-id><pub-id pub-id-type="pmid">23708142</pub-id><pub-id pub-id-type="pmcid">PMC3703870</pub-id></element-citation></ref><ref id="B57-antibodies-12-00041"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harold</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hollingworth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerrish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamshere</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Singh Pahwa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moskvina</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dowzell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#8217;s disease</article-title><source>Nat. Genet.</source><year>2013</year><volume>41</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.440</pub-id><pub-id pub-id-type="pmcid">PMC2845877</pub-id><pub-id pub-id-type="pmid">19734902</pub-id></element-citation></ref><ref id="B58-antibodies-12-00041"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stefansson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Snaedal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bjornsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huttenlocher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Levey</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Lah</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Variant of TREM2 Associated with the Risk of Alzheimer&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211103</pub-id><pub-id pub-id-type="pmid">23150908</pub-id><pub-id pub-id-type="pmcid">PMC3677583</pub-id></element-citation></ref><ref id="B59-antibodies-12-00041"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thambisetty</surname><given-names>M.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nalls</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sojkova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype</article-title><source>Biol. Psychiatry</source><year>2013</year><volume>73</volume><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.08.015</pub-id><pub-id pub-id-type="pmid">23022416</pub-id><pub-id pub-id-type="pmcid">PMC3535537</pub-id></element-citation></ref><ref id="B60-antibodies-12-00041"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gouras</surname><given-names>G.K.</given-names></name></person-group><article-title>Plaque formation and the intraneuronal accumulation of &#946;-amyloid in Alzheimer&#8217;s disease</article-title><source>Pathol. Int.</source><year>2017</year><volume>67</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1111/pin.12520</pub-id><pub-id pub-id-type="pmid">28261941</pub-id></element-citation></ref><ref id="B61-antibodies-12-00041"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajan</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Weuve</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.A.</given-names></name></person-group><article-title>Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia</article-title><source>Neurology</source><year>2015</year><volume>85</volume><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001774</pub-id><pub-id pub-id-type="pmid">26109713</pub-id><pub-id pub-id-type="pmcid">PMC4560057</pub-id></element-citation></ref><ref id="B62-antibodies-12-00041"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name></person-group><article-title>The evolution of preclinical Alzheimer&#8217;s disease: Implications for prevention trials</article-title><source>Neuron</source><year>2014</year><volume>84</volume><fpage>608</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.10.038</pub-id><pub-id pub-id-type="pmid">25442939</pub-id><pub-id pub-id-type="pmcid">PMC4285623</pub-id></element-citation></ref><ref id="B63-antibodies-12-00041"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mordechai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shufan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Porat Katz</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>A.</given-names></name></person-group><article-title>Early diagnosis of Alzheimer&#8217;s disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses</article-title><source>Analyst</source><year>2017</year><volume>142</volume><fpage>1276</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1039/C6AN01580H</pub-id><pub-id pub-id-type="pmid">27827489</pub-id></element-citation></ref><ref id="B64-antibodies-12-00041"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Polito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sorbi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pupi</surname><given-names>A.</given-names></name></person-group><article-title>Rethinking on the concept of biomarkers in preclinical Alzheimer&#8217;s disease</article-title><source>Neurol. Sci.</source><year>2016</year><volume>37</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1007/s10072-016-2477-1</pub-id><pub-id pub-id-type="pmid">26792010</pub-id></element-citation></ref><ref id="B65-antibodies-12-00041"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davatzikos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Da</surname><given-names>X.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Zee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shacklett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parmpi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers</article-title><source>NeuroImage Clin.</source><year>2014</year><volume>4</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2013.11.010</pub-id><pub-id pub-id-type="pmid">24371799</pub-id><pub-id pub-id-type="pmcid">PMC3871290</pub-id></element-citation></ref><ref id="B66-antibodies-12-00041"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriksen</surname><given-names>K.</given-names></name><name name-style="western"><surname>O&#8217;Bryant</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Montine</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Jeromin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>L&#246;nneborg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The future of blood-based biomarkers for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement.</source><year>2014</year><volume>10</volume><fpage>115</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.01.013</pub-id><pub-id pub-id-type="pmid">23850333</pub-id><pub-id pub-id-type="pmcid">PMC4128378</pub-id></element-citation></ref><ref id="B67-antibodies-12-00041"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lautner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U.</given-names></name><name name-style="western"><surname>&#214;hrfelt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Portelius</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bjerke</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#246;ltt&#228;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ros&#233;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>G.</given-names></name><etal/></person-group><article-title>CSF and blood biomarkers for the diagnosis of Alzheimer&#8217;s disease: A systematic review and meta-analysis</article-title><source>Lancet Neurol.</source><year>2016</year><volume>15</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)00070-3</pub-id><pub-id pub-id-type="pmid">27068280</pub-id></element-citation></ref><ref id="B68-antibodies-12-00041"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frankfort</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tulner</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Campen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.</given-names></name></person-group><article-title>Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature</article-title><source>Curr. Clin. Pharmacol.</source><year>2008</year><volume>3</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.2174/157488408784293723</pub-id><pub-id pub-id-type="pmid">18700307</pub-id></element-citation></ref><ref id="B69-antibodies-12-00041"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spies</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Van Groen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>J.A.H.R.</given-names></name></person-group><article-title>Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease</article-title><source>Front. Biosci.</source><year>2012</year><volume>17</volume><fpage>2024</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.2741/4035</pub-id><pub-id pub-id-type="pmid">22652762</pub-id></element-citation></ref><ref id="B70-antibodies-12-00041"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skillb&#228;ck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Farahmand</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Ros&#233;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>N&#228;gga</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kilander</surname><given-names>L.</given-names></name><name name-style="western"><surname>Religa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wimo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schott</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid tau and amyloid-&#946;1-42 in patients with dementia</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>2716</fpage><lpage>2731</lpage><pub-id pub-id-type="doi">10.1093/brain/awv181</pub-id><pub-id pub-id-type="pmid">26133663</pub-id></element-citation></ref><ref id="B71-antibodies-12-00041"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Pratico</surname><given-names>D.</given-names></name><name name-style="western"><surname>Seltzer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Geschwind</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Rodriguez-Agudelo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schaffer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sokolow</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biochemical markers in persons with preclinical familial Alzheimer disease</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000303973.71803.81</pub-id><pub-id pub-id-type="pmid">18509095</pub-id></element-citation></ref><ref id="B72-antibodies-12-00041"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanveer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>R.</given-names></name></person-group><article-title>FAF-DRVFL: Fuzzy activation function based deep random vector functional links network for early diagnosis of Alzheimer disease</article-title><source>Appl. Soft Comput.</source><year>2021</year><volume>106</volume><fpage>107371</fpage><pub-id pub-id-type="doi">10.1016/j.asoc.2021.107371</pub-id></element-citation></ref><ref id="B73-antibodies-12-00041"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Knochel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balaban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kraft</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kopf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Prvulovic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Oertel-Knochel</surname><given-names>V.</given-names></name></person-group><article-title>Integrated Biomarkers for Depression in Alzheimer&#8217;s Disease: A Critical Review</article-title><source>Curr. Alzheimer Res.</source><year>2017</year><volume>14</volume><fpage>441</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.2174/1567205013666160603011256</pub-id><pub-id pub-id-type="pmid">27335045</pub-id></element-citation></ref><ref id="B74-antibodies-12-00041"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dur&#227;es</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>E.</given-names></name></person-group><article-title>Old drugs as new treatments for neurodegenerative diseases</article-title><source>Pharmaceuticals</source><year>2018</year><volume>11</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.3390/ph11020044</pub-id><pub-id pub-id-type="pmid">29751602</pub-id><pub-id pub-id-type="pmcid">PMC6027455</pub-id></element-citation></ref><ref id="B75-antibodies-12-00041"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allsop</surname><given-names>D.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fullwood</surname><given-names>N.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aggidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dale</surname><given-names>M.</given-names></name></person-group><article-title>A novel approach to the therapy of Alzheimer&#8217;s disease based on peptide nanoliposome inhibitors of A&#946; and tau aggregation</article-title><source>J. Prev. Alzheimers Dis.</source><year>2017</year><volume>4</volume><fpage>385</fpage><lpage>386</lpage></element-citation></ref><ref id="B76-antibodies-12-00041"><label>76.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration (FDA)</collab></person-group><article-title>FDA Grants Accelerated Approval for Alzheimer&#8217;s Drug|FDA</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-06-14">(accessed on 14 June 2022)</date-in-citation></element-citation></ref><ref id="B77-antibodies-12-00041"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delrieu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caillaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name></person-group><article-title>Managing cognitive dysfunction through the continuum of alzheimers disease: Role of pharmacotherapy</article-title><source>CNS Drugs</source><year>2011</year><volume>25</volume><fpage>213</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.2165/11539810-000000000-00000</pub-id><pub-id pub-id-type="pmid">21323393</pub-id></element-citation></ref><ref id="B78-antibodies-12-00041"><label>78.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>McGeer</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Schulzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>E.G.</given-names></name></person-group><article-title>Anti-inflammatory agents as possible protective factors for Alzheimer&#8217;s disease: Analysis of relevant epidemiological studies</article-title><source>Neuroinflammatory Mechanisms in Alzheimer&#8217;s Disease Basic and Clinical Research</source><publisher-name>Birkh&#228;user</publisher-name><publisher-loc>Basel, Switzerland</publisher-loc><year>2001</year><fpage>53</fpage><lpage>64</lpage></element-citation></ref><ref id="B79-antibodies-12-00041"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galimberti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scarpini</surname><given-names>E.</given-names></name></person-group><article-title>Progress in Alzheimer&#8217;s disease</article-title><source>J. Neurol.</source><year>2012</year><volume>259</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1007/s00415-011-6145-3</pub-id><pub-id pub-id-type="pmid">21706152</pub-id></element-citation></ref><ref id="B80-antibodies-12-00041"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lemere</surname><given-names>C.A.</given-names></name></person-group><article-title>Amyloid-&#946; Immunotherapy for Alzheimer&#8217;s Disease</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2010</year><volume>9</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.2174/187152710791012017</pub-id><pub-id pub-id-type="pmid">20205640</pub-id><pub-id pub-id-type="pmcid">PMC2895488</pub-id></element-citation></ref><ref id="B81-antibodies-12-00041"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Can Alzheimer disease be prevented by amyloid-&#914; immunotherapy?</article-title><source>Nat. Rev. Neurol.</source><year>2010</year><volume>6</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2009.219</pub-id><pub-id pub-id-type="pmid">20140000</pub-id><pub-id pub-id-type="pmcid">PMC2864089</pub-id></element-citation></ref><ref id="B82-antibodies-12-00041"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabir</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>B.</given-names></name><name name-style="western"><surname>Das</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Perveen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>G.M.</given-names></name></person-group><article-title>Emerging Promise of Immunotherapy for Alzheimer&#8217;s Disease: A New Hope for the Development of Alzheimer&#8217;s Vaccine</article-title><source>Curr. Top. Med. Chem.</source><year>2020</year><volume>20</volume><fpage>1214</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.2174/1568026620666200422105156</pub-id><pub-id pub-id-type="pmid">32321405</pub-id></element-citation></ref><ref id="B83-antibodies-12-00041"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koppel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanan-Aharon</surname><given-names>E.</given-names></name></person-group><article-title>Disaggregation of Alzheimer &#946;-amyloid by site-directed mAb</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1997</year><volume>94</volume><fpage>4109</fpage><lpage>4112</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.8.4109</pub-id><pub-id pub-id-type="pmid">9108113</pub-id><pub-id pub-id-type="pmcid">PMC20576</pub-id></element-citation></ref><ref id="B84-antibodies-12-00041"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barbour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grajeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guido</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson-Wood</surname><given-names>K.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Immunization with amyloid-[beta] attenuates Alzheimer-disease-like pathology in the PDAPP mouse</article-title><source>Nature</source><year>1999</year><volume>400</volume><fpage>173</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/22124</pub-id><pub-id pub-id-type="pmid">10408445</pub-id></element-citation></ref><ref id="B85-antibodies-12-00041"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asuni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Boutajangout</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scholtzova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Quartermain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>E.M.</given-names></name></person-group><article-title>Vaccination of Alzheimer&#8217;s model mice with A&#946; derivative in alum adjuvant reduces A&#946; burden without microhemorrhages</article-title><source>Eur. J. Neurosci.</source><year>2006</year><volume>24</volume><fpage>2530</fpage><lpage>2542</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.05149.x</pub-id><pub-id pub-id-type="pmid">17100841</pub-id><pub-id pub-id-type="pmcid">PMC1779823</pub-id></element-citation></ref><ref id="B86-antibodies-12-00041"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemere</surname><given-names>C.A.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease: Hoops and hurdles</article-title><source>Mol. Neurodegener.</source><year>2013</year><volume>8</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-8-36</pub-id><pub-id pub-id-type="pmid">24148220</pub-id><pub-id pub-id-type="pmcid">PMC4015631</pub-id></element-citation></ref><ref id="B87-antibodies-12-00041"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotilinek</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bacskai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Westerman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawarabayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashe</surname><given-names>K.H.</given-names></name></person-group><article-title>Reversible memory loss in a mouse transgenic model of Alzheimer&#8217;s disease</article-title><source>J. Neurosci.</source><year>2002</year><volume>22</volume><fpage>6331</fpage><lpage>6335</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-15-06331.2002</pub-id><pub-id pub-id-type="pmid">12151510</pub-id><pub-id pub-id-type="pmcid">PMC6758140</pub-id></element-citation></ref><ref id="B88-antibodies-12-00041"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohn</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Vyas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hernandez-Estrada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nichol</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Head</surname><given-names>E.</given-names></name></person-group><article-title>Lack of pathology in a triple transgenic mouse model of Alzheimer&#8217;s disease after overexpression of the anti-apoptotic protein Bcl-2</article-title><source>J. Neurosci.</source><year>2008</year><volume>28</volume><fpage>3051</fpage><lpage>3059</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5620-07.2008</pub-id><pub-id pub-id-type="pmid">18354008</pub-id><pub-id pub-id-type="pmcid">PMC6670712</pub-id></element-citation></ref><ref id="B89-antibodies-12-00041"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Agholme</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brorsson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Marcusson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hallbeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>S.</given-names></name></person-group><article-title>Spreading of amyloid-&#946; peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance</article-title><source>Neurobiol. Dis.</source><year>2014</year><volume>65</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.12.019</pub-id><pub-id pub-id-type="pmid">24412310</pub-id></element-citation></ref><ref id="B90-antibodies-12-00041"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winslow</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Moussaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Post</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Berezovska</surname><given-names>O.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>P.J.</given-names></name></person-group><article-title>Convergence of pathology in dementia with Lewy bodies and Alzheimer&#8217;s disease: A role for the novel interaction of alpha-synuclein and presenilin 1 in disease</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>1958</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1093/brain/awu119</pub-id><pub-id pub-id-type="pmid">24860142</pub-id><pub-id pub-id-type="pmcid">PMC4065023</pub-id></element-citation></ref><ref id="B91-antibodies-12-00041"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morales</surname><given-names>R.</given-names></name><name name-style="western"><surname>Callegari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C.</given-names></name></person-group><article-title>Prion-like features of misfolded A&#946; and tau aggregates</article-title><source>Virus Res.</source><year>2015</year><volume>207</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.12.031</pub-id><pub-id pub-id-type="pmid">25575736</pub-id></element-citation></ref><ref id="B92-antibodies-12-00041"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meraz-R&#237;os</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lira-De Le&#243;n</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Campos-Pe&#241;a</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Anda-Hern&#225;ndez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mena-L&#243;pez</surname><given-names>R.</given-names></name></person-group><article-title>Tau oligomers and aggregation in Alzheimer&#8217;s disease</article-title><source>J. Neurochem.</source><year>2010</year><volume>112</volume><fpage>1353</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06511.x</pub-id><pub-id pub-id-type="pmid">19943854</pub-id></element-citation></ref><ref id="B93-antibodies-12-00041"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jappelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maji</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Desplats</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aigner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hetzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vilar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campioni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>In vivo demonstration that &#945;-synuclein oligomers are toxic</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>4194</fpage><lpage>4199</lpage><pub-id pub-id-type="doi">10.1073/pnas.1100976108</pub-id><pub-id pub-id-type="pmid">21325059</pub-id><pub-id pub-id-type="pmcid">PMC3053976</pub-id></element-citation></ref><ref id="B94-antibodies-12-00041"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lashuel</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Overk</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Oueslati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>The many faces of &#945;-synuclein: From structure and toxicity to therapeutic target</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nrn3406</pub-id><pub-id pub-id-type="pmid">23254192</pub-id><pub-id pub-id-type="pmcid">PMC4295774</pub-id></element-citation></ref><ref id="B95-antibodies-12-00041"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clinton</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Blurton-Jones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Myczek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>LaFerla</surname><given-names>F.M.</given-names></name></person-group><article-title>Synergistic interactions between A&#946;, tau, and &#945;-synuclein: Acceleration of neuropathology and cognitive decline</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>7281</fpage><lpage>7289</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0490-10.2010</pub-id><pub-id pub-id-type="pmid">20505094</pub-id><pub-id pub-id-type="pmcid">PMC3308018</pub-id></element-citation></ref><ref id="B96-antibodies-12-00041"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease</article-title><source>Proc. J. Intern. Med.</source><year>2011</year><volume>269</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2796.2010.02315.x</pub-id><pub-id pub-id-type="pmid">21158978</pub-id><pub-id pub-id-type="pmcid">PMC3074967</pub-id></element-citation></ref><ref id="B97-antibodies-12-00041"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilcock</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sudduth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Greenstein</surname><given-names>A.</given-names></name></person-group><article-title>P1&#8211;027: Intracranial administration of Gammagard IVIg lowers amyloid and modulates neuroinflammatory profiles along a different time-course than anti-beta-amyloid IgG: Implications for mechanism of action</article-title><source>Alzheimers Dement.</source><year>2013</year><volume>9</volume><fpage>P162</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.05.247</pub-id></element-citation></ref><ref id="B98-antibodies-12-00041"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>P.</given-names></name><name name-style="western"><surname>Switzer</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Jankowsky</surname><given-names>J.L.</given-names></name></person-group><article-title>Robust amyloid clearance in a mouse model of Alzheimer&#8217;s disease provides novel insights into the mechanism of amyloid-&#946; immunotherapy</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>4124</fpage><lpage>4136</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5077-10.2011</pub-id><pub-id pub-id-type="pmid">21411653</pub-id><pub-id pub-id-type="pmcid">PMC3074951</pub-id></element-citation></ref><ref id="B99-antibodies-12-00041"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rockenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weninger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>C.</given-names></name><name name-style="western"><surname>Adame</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schmidhuber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santic</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schneeberger</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy</article-title><source>Mol. Neurodegener.</source><year>2015</year><volume>10</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s13024-015-0008-9</pub-id><pub-id pub-id-type="pmid">25886309</pub-id><pub-id pub-id-type="pmcid">PMC4411775</pub-id></element-citation></ref><ref id="B100-antibodies-12-00041"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMattos</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Bales</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Brain to plasma amyloid-&#946; efflux: A measure of brain amyloid burden in a mouse model of Alzheimer&#8217;s disease</article-title><source>Science</source><year>2002</year><volume>295</volume><fpage>2264</fpage><lpage>2267</lpage><pub-id pub-id-type="doi">10.1126/science.1067568</pub-id><pub-id pub-id-type="pmid">11910111</pub-id></element-citation></ref><ref id="B101-antibodies-12-00041"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MR</surname><given-names>F.</given-names></name><name name-style="western"><surname>JR</surname><given-names>B.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease</article-title><source>Neurol. Clin.</source><year>2013</year><volume>31</volume><fpage>869</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">23896510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2013.03.012</pub-id></element-citation></ref><ref id="B102-antibodies-12-00041"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deane</surname><given-names>R.</given-names></name><name name-style="western"><surname>Du Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Submamaryan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>LaRue</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hogg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Manness</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>RAGE mediates amyloid-&#946; peptide transport across the blood-brain barrier and accumulation in brain</article-title><source>Nat. Med.</source><year>2003</year><volume>9</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/nm890</pub-id><pub-id pub-id-type="pmid">12808450</pub-id></element-citation></ref><ref id="B103-antibodies-12-00041"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wicklund</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lacor</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Nordberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marutle</surname><given-names>A.</given-names></name></person-group><article-title>Different &#946;-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity</article-title><source>Neurobiol. Aging</source><year>2012</year><volume>33</volume><fpage>825.e1</fpage><lpage>825.e13</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.05.003</pub-id><pub-id pub-id-type="pmid">21683475</pub-id></element-citation></ref><ref id="B104-antibodies-12-00041"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcantar</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name></person-group><article-title>P1-255: Direct observation of the kinetic mechanisms for A&#223; peptide aggregation: Towards elucidating Alzheimer plaque dissolution</article-title><source>Alzheimers Dement.</source><year>2010</year><volume>6</volume><fpage>S247</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2010.05.807</pub-id></element-citation></ref><ref id="B105-antibodies-12-00041"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMattos</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Bales</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dodart</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Peripheral anti-A&#946; antibody alters CNS and plasma A&#946; clearance and decreases brain A&#946; burden in a mouse model of Alzheimer&#8217;s disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>8850</fpage><lpage>8855</lpage><pub-id pub-id-type="doi">10.1073/pnas.151261398</pub-id><pub-id pub-id-type="pmid">11438712</pub-id><pub-id pub-id-type="pmcid">PMC37524</pub-id></element-citation></ref><ref id="B106-antibodies-12-00041"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goni</surname><given-names>F.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease</article-title><source>Biochem. Pharmacol.</source><year>2014</year><volume>88</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.12.020</pub-id><pub-id pub-id-type="pmid">24412277</pub-id><pub-id pub-id-type="pmcid">PMC3972315</pub-id></element-citation></ref><ref id="B107-antibodies-12-00041"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B.</given-names></name></person-group><article-title>Immunological and anti-chaperone therapeutic approaches for Alzheimer disease</article-title><source>Proc. Brain Pathol.</source><year>2005</year><volume>15</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2005.tb00102.x</pub-id><pub-id pub-id-type="pmid">15779239</pub-id><pub-id pub-id-type="pmcid">PMC8095760</pub-id></element-citation></ref><ref id="B108-antibodies-12-00041"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Millais</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Donoghue</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of the safety and immunogenicity of synthetic A&#946;42 (AN1792) in patients with AD</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000148604.77591.67</pub-id><pub-id pub-id-type="pmid">15642910</pub-id></element-citation></ref><ref id="B109-antibodies-12-00041"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pride</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name></person-group><article-title>Progress in the active immunotherapeutic approach to Alzheimer&#8217;s disease: Clinical investigations into AN1792-associated meningoencephalitis</article-title><source>Proc. Neurodegener. Dis.</source><year>2008</year><volume>5</volume><fpage>194</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1159/000113700</pub-id><pub-id pub-id-type="pmid">18322388</pub-id></element-citation></ref><ref id="B110-antibodies-12-00041"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Eisner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boada Rovira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forette</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Clinical effects of A&#946; immunization (AN1792) in patients with AD in an interrupted trial</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159740.16984.3C</pub-id><pub-id pub-id-type="pmid">15883316</pub-id></element-citation></ref><ref id="B111-antibodies-12-00041"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name></person-group><article-title>SYMPOSIUM: Clearance of A&#946; from the Brain in Alzheimer&#8217;Disease: The Role of the Immune System in Clearance of A&#946; from the Brain</article-title><source>Brain Pathol.</source><year>2008</year><volume>18</volume><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2008.00134.x</pub-id><pub-id pub-id-type="pmid">18363937</pub-id><pub-id pub-id-type="pmcid">PMC8095633</pub-id></element-citation></ref><ref id="B112-antibodies-12-00041"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rovira</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>M.L.S.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Costa-Juss&#225;</surname><given-names>F.</given-names></name></person-group><article-title>Neuropathology and Pathogenesis of Encephalitis following Amyloid &#946; Immunization in Alzheimer&#8217;s Disease</article-title><source>Brain Pathol.</source><year>2004</year><volume>14</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2004.tb00493.x</pub-id><pub-id pub-id-type="pmid">14997933</pub-id><pub-id pub-id-type="pmcid">PMC8095815</pub-id></element-citation></ref><ref id="B113-antibodies-12-00041"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Adame</surname><given-names>A.</given-names></name><name name-style="western"><surname>Crews</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Games</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>D.</given-names></name></person-group><article-title>A&#946; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000148590.39911.DF</pub-id><pub-id pub-id-type="pmid">15642916</pub-id></element-citation></ref><ref id="B114-antibodies-12-00041"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vlachouli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Games</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A&#946; species removal after A&#946;42 immunization</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>2006</year><volume>65</volume><fpage>1040</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000240466.10758.ce</pub-id><pub-id pub-id-type="pmid">17086100</pub-id></element-citation></ref><ref id="B115-antibodies-12-00041"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bombois</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maurage</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Gompel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deramecourt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mackowiak-Cordoliani</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Lavielle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Delacourte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pasquier</surname><given-names>F.</given-names></name></person-group><article-title>Absence of &#946;-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia</article-title><source>Arch. Neurol.</source><year>2007</year><volume>64</volume><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.4.583</pub-id><pub-id pub-id-type="pmid">17420322</pub-id></element-citation></ref><ref id="B116-antibodies-12-00041"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gody&#324;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jo&#324;czyk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Panek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Malawska</surname><given-names>B.</given-names></name></person-group><article-title>Therapeutic strategies for Alzheimer&#8217;s disease in clinical trials</article-title><source>Pharmacol. Reports</source><year>2016</year><volume>68</volume><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2015.07.006</pub-id><pub-id pub-id-type="pmid">26721364</pub-id></element-citation></ref><ref id="B117-antibodies-12-00041"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St-Amour</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cicchetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Calon</surname><given-names>F.</given-names></name></person-group><article-title>Immunotherapies in Alzheimer&#8217;s disease: Too much, too little, too late or off-target?</article-title><source>Acta Neuropathol.</source><year>2016</year><volume>131</volume><fpage>481</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s00401-015-1518-9</pub-id><pub-id pub-id-type="pmid">26689922</pub-id></element-citation></ref><ref id="B118-antibodies-12-00041"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiessner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wiederhold</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Tissot</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>P.</given-names></name><name name-style="western"><surname>Danner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>L&#252;&#246;nd</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ortmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reichwald</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The second-generation active A&#946; immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>9323</fpage><lpage>9331</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0293-11.2011</pub-id><pub-id pub-id-type="pmid">21697382</pub-id><pub-id pub-id-type="pmcid">PMC6623465</pub-id></element-citation></ref><ref id="B119-antibodies-12-00041"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Minthon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Floesser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imbert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dumortier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lundmark</surname><given-names>J.</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and antibody response of active A&#946; immunotherapy with CAD106 in patients with Alzheimer&#8217;s disease: Randomised, double-blind, placebo-controlled, first-in-human study</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70140-0</pub-id><pub-id pub-id-type="pmid">22677258</pub-id></element-citation></ref><ref id="B120-antibodies-12-00041"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name></person-group><article-title>Active immunotherapy for Alzheimer&#8217;s disease</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>571</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70136-9</pub-id><pub-id pub-id-type="pmid">22677257</pub-id><pub-id pub-id-type="pmcid">PMC3560289</pub-id></element-citation></ref><ref id="B121-antibodies-12-00041"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M.</given-names></name></person-group><article-title>Anti-amyloid-&#946; immunotherapy in alzheimer&#8217;s disease: Acc-001 clinical trials are ongoing</article-title><source>J. Alzheimers Dis.</source><year>2009</year><volume>17</volume><fpage>243</fpage><pub-id pub-id-type="doi">10.3233/JAD-2009-1118</pub-id><pub-id pub-id-type="pmid">19502708</pub-id></element-citation></ref><ref id="B122-antibodies-12-00041"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otava</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mattner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>W.</given-names></name></person-group><article-title>Development of AFFITOPE vaccines for Alzheimer&#8217;s Disease (AD)&#8212;From concept to clinical testing</article-title><source>J. Nutr. Health Aging</source><year>2009</year><volume>13</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/s12603-009-0070-5</pub-id><pub-id pub-id-type="pmid">19262965</pub-id></element-citation></ref><ref id="B123-antibodies-12-00041"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenmann</surname><given-names>H.</given-names></name></person-group><article-title>Immunotherapy for Targeting Tau Pathology in Alzheimer&#8217;s Disease and Tauopathies</article-title><source>Curr. Alzheimer Res.</source><year>2013</year><volume>10</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.2174/1567205011310030001</pub-id><pub-id pub-id-type="pmid">23534533</pub-id></element-citation></ref><ref id="B124-antibodies-12-00041"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galimberti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scarpini</surname><given-names>E.</given-names></name></person-group><article-title>Disease-modifying treatments for Alzheimer&#8217;s disease</article-title><source>Ther. Adv. Neurol. Disord.</source><year>2011</year><volume>4</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1177/1756285611404470</pub-id><pub-id pub-id-type="pmid">21765871</pub-id><pub-id pub-id-type="pmcid">PMC3131171</pub-id></element-citation></ref><ref id="B125-antibodies-12-00041"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bohrmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>G&#246;pfert</surname><given-names>U.</given-names></name><name name-style="western"><surname>Oroszlan-Szovik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ozmen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gr&#252;ninger</surname><given-names>F.</given-names></name></person-group><article-title>Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer&#8217;s disease</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>2834</fpage><lpage>2846</lpage><pub-id pub-id-type="doi">10.1093/brain/awu213</pub-id><pub-id pub-id-type="pmid">25085375</pub-id></element-citation></ref><ref id="B126-antibodies-12-00041"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Devos</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Commins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Pitstick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nobuhara</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#8217;s disease brain</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8490</fpage><pub-id pub-id-type="doi">10.1038/ncomms9490</pub-id><pub-id pub-id-type="pmid">26458742</pub-id><pub-id pub-id-type="pmcid">PMC4608380</pub-id></element-citation></ref><ref id="B127-antibodies-12-00041"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobuhara</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>DeVos</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Commins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>I.</given-names></name><name name-style="western"><surname>Frosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pitstick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro</article-title><source>Am. J. Pathol.</source><year>2017</year><volume>187</volume><fpage>1399</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2017.01.022</pub-id><pub-id pub-id-type="pmid">28408124</pub-id><pub-id pub-id-type="pmcid">PMC5455060</pub-id></element-citation></ref><ref id="B128-antibodies-12-00041"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanamandra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kfoury</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Wozniak</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Anti-tau antibodies that block tau aggregate seeding invitro markedly decrease pathology and improve cognition in vivo</article-title><source>Neuron</source><year>2013</year><volume>80</volume><fpage>402</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.07.046</pub-id><pub-id pub-id-type="pmid">24075978</pub-id><pub-id pub-id-type="pmcid">PMC3924573</pub-id></element-citation></ref><ref id="B129-antibodies-12-00041"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutajangout</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quartermain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>E.M.</given-names></name></person-group><article-title>Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>16559</fpage><lpage>16566</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4363-10.2010</pub-id><pub-id pub-id-type="pmid">21147995</pub-id><pub-id pub-id-type="pmcid">PMC3135981</pub-id></element-citation></ref><ref id="B130-antibodies-12-00041"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Murayama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suhara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>A.</given-names></name></person-group><article-title>Biochemical distribution of tau protein in synaptosomal fraction of transgenic mice expressing human p301l tau</article-title><source>Front. Neurol.</source><year>2014</year><volume>5</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.3389/fneur.2014.00026</pub-id><pub-id pub-id-type="pmid">24653715</pub-id><pub-id pub-id-type="pmcid">PMC3949102</pub-id></element-citation></ref><ref id="B131-antibodies-12-00041"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asuni</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Boutajangout</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quartermain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sigurdsson</surname><given-names>E.M.</given-names></name></person-group><article-title>Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><fpage>9115</fpage><lpage>9129</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2361-07.2007</pub-id><pub-id pub-id-type="pmid">17715348</pub-id><pub-id pub-id-type="pmcid">PMC6672191</pub-id></element-citation></ref><ref id="B132-antibodies-12-00041"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boimel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grigoriadis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lourbopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haber</surname><given-names>E.</given-names></name><name name-style="western"><surname>Abramsky</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rosenmann</surname><given-names>H.</given-names></name></person-group><article-title>Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice</article-title><source>Exp. Neurol.</source><year>2010</year><volume>224</volume><fpage>472</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2010.05.010</pub-id><pub-id pub-id-type="pmid">20546729</pub-id></element-citation></ref><ref id="B133-antibodies-12-00041"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golde</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Petrucelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name></person-group><article-title>Targeting A&#946; and tau in Alzheimer&#8217;s disease, an early interim report</article-title><source>Exp. Neurol.</source><year>2010</year><volume>223</volume><fpage>252</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2009.07.035</pub-id><pub-id pub-id-type="pmid">19716367</pub-id><pub-id pub-id-type="pmcid">PMC2864363</pub-id></element-citation></ref><ref id="B134-antibodies-12-00041"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theunis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crespo-Biel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gafner</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pihlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#243;pez-Deber</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Adolfsson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chuard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ndao</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e0072301</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072301</pub-id><pub-id pub-id-type="pmid">23977276</pub-id><pub-id pub-id-type="pmcid">PMC3747157</pub-id></element-citation></ref><ref id="B135-antibodies-12-00041"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name></person-group><article-title>Early investigational drugs targeting tau protein for the treatment of Alzheimers disease</article-title><source>Expert Opin. Investig. Drugs</source><year>2015</year><volume>24</volume><fpage>1355</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1517/13543784.2015.1075002</pub-id><pub-id pub-id-type="pmcid">PMC5502785</pub-id><pub-id pub-id-type="pmid">26289787</pub-id></element-citation></ref><ref id="B136-antibodies-12-00041"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kalback</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Esh</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Kokjohn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Van Vickle</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Luehrs</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brune</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Amyloid-&#946; peptide remnants in AN-1792-immunized Alzheimer&#8217;s disease patients: A biochemical analysis</article-title><source>Am. J. Pathol.</source><year>2006</year><volume>169</volume><fpage>1048</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2006.060269</pub-id><pub-id pub-id-type="pmid">16936277</pub-id><pub-id pub-id-type="pmcid">PMC1698828</pub-id></element-citation></ref><ref id="B137-antibodies-12-00041"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group><article-title>Biomarkers in amyloid-&#946; immunotherapy trials in Alzheimer&#8217;s disease</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.154</pub-id><pub-id pub-id-type="pmid">23799530</pub-id><pub-id pub-id-type="pmcid">PMC3857643</pub-id></element-citation></ref><ref id="B138-antibodies-12-00041"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name></person-group><article-title>Active immunotherapy options for Alzheimer&#8217;s disease</article-title><source>Alzheimers Res. Ther.</source><year>2014</year><volume>6</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/alzrt237</pub-id><pub-id pub-id-type="pmid">24476230</pub-id><pub-id pub-id-type="pmcid">PMC3979042</pub-id></element-citation></ref><ref id="B139-antibodies-12-00041"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Vostiar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vitaliti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sovago</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>A.</given-names></name></person-group><article-title>Long-term treatment with active A&#946; immunotherapy with CAD106 in mild Alzheimer&#8217;s disease</article-title><source>Alzheimers Res. Ther.</source><year>2015</year><volume>7</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s13195-015-0108-3</pub-id><pub-id pub-id-type="pmid">25918556</pub-id><pub-id pub-id-type="pmcid">PMC4410460</pub-id></element-citation></ref><ref id="B140-antibodies-12-00041"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sadowsky</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leterme</surname><given-names>G.L.P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name></person-group><article-title>Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer&#8217;s disease</article-title><source>J. Alzheimers Dis.</source><year>2016</year><volume>51</volume><fpage>1131</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.3233/JAD-150376</pub-id><pub-id pub-id-type="pmid">26967206</pub-id></element-citation></ref><ref id="B141-antibodies-12-00041"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.S.</given-names></name></person-group><article-title>Efficacy and safety of anti-amyloid-&#946; immunotherapy for Alzheimer&#8217;s disease: A systematic review and network meta-analysis</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2017</year><volume>4</volume><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1002/acn3.469</pub-id><pub-id pub-id-type="pmid">29296624</pub-id><pub-id pub-id-type="pmcid">PMC5740249</pub-id></element-citation></ref><ref id="B142-antibodies-12-00041"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pihlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vukicevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gafner</surname><given-names>V.</given-names></name><name name-style="western"><surname>Piorkowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chuard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Giriens</surname><given-names>V.</given-names></name><name name-style="western"><surname>Valdes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nazeeruddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>O2-13-03: Efficacy of ACI-35, A Liposomal Anti-Phospho Tau Vaccine in Two Different Mouse Models of Alzheimer&#8217;s Disease</article-title><source>Alzheimers Dement.</source><year>2016</year><volume>12</volume><fpage>P260</fpage><lpage>P261</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.06.468</pub-id></element-citation></ref><ref id="B143-antibodies-12-00041"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattepoel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kulic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nitsch</surname><given-names>R.M.</given-names></name></person-group><article-title>Chronic intranasal treatment with an anti-A&#946;30-42 scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer&#8217;s disease</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e18296</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018296</pub-id><pub-id pub-id-type="pmid">21483675</pub-id><pub-id pub-id-type="pmcid">PMC3071717</pub-id></element-citation></ref><ref id="B144-antibodies-12-00041"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrushina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ghochikyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mkrtichyan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mamikonyan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Movsesyan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ajdari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vasilevko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Karapetyan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agadjanyan</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice</article-title><source>J. Neuroinflamm.</source><year>2008</year><volume>5</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-5-42</pub-id><pub-id pub-id-type="pmcid">PMC2567310</pub-id><pub-id pub-id-type="pmid">18823564</pub-id></element-citation></ref><ref id="B145-antibodies-12-00041"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lebson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Nash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selenica</surname><given-names>M.L.B.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.N.</given-names></name></person-group><article-title>Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load</article-title><source>J. Neuroimmune Pharmacol.</source><year>2012</year><volume>7</volume><fpage>202</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1007/s11481-011-9329-9</pub-id><pub-id pub-id-type="pmid">22198698</pub-id></element-citation></ref><ref id="B146-antibodies-12-00041"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mavoungou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schindowski</surname><given-names>K.</given-names></name></person-group><article-title>Passive anti-amyloid immunotherapy in Alzheimer&#8217;s disease: What are the most promising targets?</article-title><source>Immun. Ageing</source><year>2013</year><volume>10</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/1742-4933-10-18</pub-id><pub-id pub-id-type="pmid">23663286</pub-id><pub-id pub-id-type="pmcid">PMC3681567</pub-id></element-citation></ref><ref id="B147-antibodies-12-00041"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Tampieri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barakos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Amyloid-related imaging abnormalities in patients with Alzheimer&#8217;s disease treated with bapineuzumab: A retrospective analysis</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70015-7</pub-id><pub-id pub-id-type="pmid">22305802</pub-id><pub-id pub-id-type="pmcid">PMC4063417</pub-id></element-citation></ref><ref id="B148-antibodies-12-00041"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doody</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vellas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kieburtz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312889</pub-id><pub-id pub-id-type="pmid">24450890</pub-id></element-citation></ref><ref id="B149-antibodies-12-00041"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klunk</surname><given-names>W.</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer&#8217;s Disease</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1304839</pub-id><pub-id pub-id-type="pmid">24450891</pub-id><pub-id pub-id-type="pmcid">PMC4159618</pub-id></element-citation></ref><ref id="B150-antibodies-12-00041"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name></person-group><article-title>Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo</article-title><source>Behav. Neurol.</source><year>2009</year><volume>21</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1155/2009/609839</pub-id><pub-id pub-id-type="pmid">19847050</pub-id><pub-id pub-id-type="pmcid">PMC2804478</pub-id></element-citation></ref><ref id="B151-antibodies-12-00041"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M.</given-names></name></person-group><article-title>Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement.</source><year>2010</year><volume>6</volume><fpage>S134</fpage><lpage>S135</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2010.05.419</pub-id></element-citation></ref><ref id="B152-antibodies-12-00041"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laskowitz</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>B.J.</given-names></name></person-group><article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease</article-title><source>Neurology</source><year>2010</year><volume>74</volume><fpage>2026</fpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181e03844</pub-id><pub-id pub-id-type="pmid">20548049</pub-id></element-citation></ref><ref id="B153-antibodies-12-00041"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raskind</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Doody</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>2061</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c67808</pub-id><pub-id pub-id-type="pmid">19923550</pub-id><pub-id pub-id-type="pmcid">PMC2790221</pub-id></element-citation></ref><ref id="B154-antibodies-12-00041"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Iwatsubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montine</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Toward defining the preclinical stages of Alzheimer&#8217;s disease: Recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement.</source><year>2011</year><volume>7</volume><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></element-citation></ref><ref id="B155-antibodies-12-00041"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sethuraman</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety and biomarker effects of solanezumab in patients with Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement.</source><year>2012</year><volume>8</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.09.224</pub-id><pub-id pub-id-type="pmid">22672770</pub-id></element-citation></ref><ref id="B156-antibodies-12-00041"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siemers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holdridge</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Sundell</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Liu-Seifert</surname><given-names>H.</given-names></name></person-group><article-title>Function and clinical meaningfulness of treatments for mild Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement. Diagnosis Assess. Dis. Monit.</source><year>2016</year><volume>2</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2016.02.006</pub-id><pub-id pub-id-type="pmcid">PMC4879645</pub-id><pub-id pub-id-type="pmid">27239541</pub-id></element-citation></ref><ref id="B157-antibodies-12-00041"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dolgin</surname><given-names>E.</given-names></name></person-group><article-title>Failed Alzheimer&#8217;s trial does not kill leading theory of disease</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nature.2016.21045</pub-id><pub-id pub-id-type="pmid">27905452</pub-id></element-citation></ref><ref id="B158-antibodies-12-00041"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacks</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Avorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kesselheim</surname><given-names>A.S.</given-names></name></person-group><article-title>The Failure of Solanezumab&#8212;How the FDA Saved Taxpayers Billions</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>376</volume><fpage>1706</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1701047</pub-id><pub-id pub-id-type="pmid">28467878</pub-id></element-citation></ref><ref id="B159-antibodies-12-00041"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name></person-group><article-title>Fluid biomarkers in clinical trials of Alzheimer&#8217;s disease therapeutics</article-title><source>Front. Neurol.</source><year>2015</year><volume>6</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.3389/fneur.2015.00186</pub-id><pub-id pub-id-type="pmid">26379620</pub-id><pub-id pub-id-type="pmcid">PMC4553391</pub-id></element-citation></ref><ref id="B160-antibodies-12-00041"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penninkilampi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brothers</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Eslick</surname><given-names>G.D.</given-names></name></person-group><article-title>Safety and Efficacy of Anti-Amyloid-&#946; Immunotherapy in Alzheimer&#8217;s Disease: A Systematic Review and Meta-Analysis</article-title><source>J. Neuroimmune Pharmacol.</source><year>2017</year><volume>12</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1007/s11481-016-9722-5</pub-id><pub-id pub-id-type="pmid">28025724</pub-id></element-citation></ref><ref id="B161-antibodies-12-00041"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanoiu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pariente</surname><given-names>J.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lobello</surname><given-names>K.</given-names></name><name name-style="western"><surname>Luscan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Styren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Long-term safety and tolerability of bapineuzumab in patients with Alzheimer&#8217;s disease in two phase 3 extension studies</article-title><source>Alzheimers Res. Ther.</source><year>2016</year><volume>8</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s13195-016-0193-y</pub-id><pub-id pub-id-type="pmid">27334799</pub-id><pub-id pub-id-type="pmcid">PMC4918115</pub-id></element-citation></ref><ref id="B162-antibodies-12-00041"><label>162.</label><element-citation publication-type="gov"><article-title>Pfizer Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00667810" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT00667810</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-15">(accessed on 15 October 2021)</date-in-citation></element-citation></ref><ref id="B163-antibodies-12-00041"><label>163.</label><element-citation publication-type="gov"><article-title>Pfizer A Long-Term Safety And Tolerability Study of Bapineuzumab in Alzheimer Disease Patients</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00996918" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT00996918</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-15">(accessed on 15 October 2021)</date-in-citation></element-citation></ref><ref id="B164-antibodies-12-00041"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roher</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Maarouf</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Kokjohn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Belden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name></person-group><article-title>Chemical and neuropathological analyses of an alzheimer&#8217;s disease patient treated with solanezumab</article-title><source>Am. J. Neurodegener. Dis.</source><year>2016</year><volume>5</volume><fpage>158</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">27725918</pub-id><pub-id pub-id-type="pmcid">PMC5043095</pub-id></element-citation></ref><ref id="B165-antibodies-12-00041"><label>165.</label><element-citation publication-type="gov"><article-title>ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01900665">NCT01900665</ext-link>. Progress of Mild Alzheimer&#8217;s Disease in Participants on Solanezumab Versus Placebo (EXPEDITION 3)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01900665" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT01900665</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-15">(accessed on 15 October 2021)</date-in-citation></element-citation></ref><ref id="B166-antibodies-12-00041"><label>166.</label><element-citation publication-type="gov"><article-title>U.S. National Institutes of Health Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss&#8212;Full Text View</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02008357" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02008357</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-06-14">(accessed on 14 June 2022)</date-in-citation></element-citation></ref><ref id="B167-antibodies-12-00041"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nikolcheva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lasser</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dukart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name></person-group><article-title>O1-10-01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer&#8217;s Disease</article-title><source>Alzheimers Dement.</source><year>2016</year><volume>12</volume><fpage>P198</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.06.346</pub-id></element-citation></ref><ref id="B168-antibodies-12-00041"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Friesenhahn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brunstein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Honigberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>R.</given-names></name></person-group><article-title>O4-11-06: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Crenezumab In Patients With Mild To Moderate Alzheimer&#8217;s Disease</article-title><source>Alzheimers Dement.</source><year>2014</year><volume>10</volume><fpage>P275</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2014.04.450</pub-id></element-citation></ref><ref id="B169-antibodies-12-00041"><label>169.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lannfelt</surname><given-names>M.I.</given-names></name></person-group><source>Immunotherapy and Biomarkers in Neurodegenerative Disorders</source><comment>Methods in Pharmacology and Toxicology</comment><person-group person-group-type="editor"><name name-style="western"><surname>Ingelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lannfelt</surname><given-names>L.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year><comment>Part F1</comment></element-citation></ref><ref id="B170-antibodies-12-00041"><label>170.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Genentech</surname><given-names>I.</given-names></name></person-group><article-title>A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer&#8217;s (Clinical Trial Identifier NCT0199884)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01998841" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT01998841</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-15">(accessed on 15 October 2021)</date-in-citation></element-citation></ref><ref id="B171-antibodies-12-00041"><label>171.</label><element-citation publication-type="gov"><article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03114657">NCT03114657</ext-link> A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer&#8217;s Disease (AD)</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ClinicalTrials.gov/show/NCT03114657" ext-link-type="uri">https://ClinicalTrials.gov/show/NCT03114657</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-06-14">(accessed on 14 June 2022)</date-in-citation></element-citation></ref><ref id="B172-antibodies-12-00041"><label>172.</label><element-citation publication-type="gov"><article-title>Pfizer A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer&#8217;s Disease</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00945672" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT00945672</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-16">(accessed on 16 October 2021)</date-in-citation></element-citation></ref><ref id="B173-antibodies-12-00041"><label>173.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Biogen Inc</collab></person-group><article-title>221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer&#8217;s Disease (EMERGE)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02484547" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02484547</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-06-14">(accessed on 14 June 2022)</date-in-citation></element-citation></ref><ref id="B174-antibodies-12-00041"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#246;ller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tegerstedt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laudon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sj&#246;dahl</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#246;derberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spens</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sahlin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Waara</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>The murine Version of BAN2401 (mAb158) selectively reduces amyloid-&#946; protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice</article-title><source>J. Alzheimer&#8217;s Dis.</source><year>2015</year><volume>43</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.3233/JAD-140741</pub-id><pub-id pub-id-type="pmid">25096615</pub-id></element-citation></ref><ref id="B175-antibodies-12-00041"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickson</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>N.</given-names></name></person-group><article-title>O3-10-04: A statistical translation of the public ban2401 study results from a bayesian to a traditional framework</article-title><source>Alzheimers Dement.</source><year>2019</year><volume>15</volume><fpage>P909</fpage><lpage>P910</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.06.4681</pub-id></element-citation></ref><ref id="B176-antibodies-12-00041"><label>176.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vegas</surname><given-names>L.</given-names></name></person-group><article-title>Second Look at BAN2401 Data Still Positive, Despite Snafu|ALZFORUM</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alzforum.org/news/conference-coverage/second-look-ban2401-data-still-positive-despite-snafu" ext-link-type="uri">https://www.alzforum.org/news/conference-coverage/second-look-ban2401-data-still-positive-despite-snafu</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-06-14">(accessed on 14 June 2022)</date-in-citation></element-citation></ref><ref id="B177-antibodies-12-00041"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lannfelt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Relkin</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Siemers</surname><given-names>E.R.</given-names></name></person-group><article-title>Amyloid-&#223;-directed immunotherapy for Alzheimer&#8217;s disease</article-title><source>J. Intern. Med.</source><year>2014</year><volume>275</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1111/joim.12168</pub-id><pub-id pub-id-type="pmid">24605809</pub-id><pub-id pub-id-type="pmcid">PMC4238820</pub-id></element-citation></ref><ref id="B178-antibodies-12-00041"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griesenauer</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kinch</surname><given-names>M.S.</given-names></name></person-group><article-title>An overview of FDA-approved vaccines &amp; their innovators</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>16</volume><fpage>1253</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1383159</pub-id><pub-id pub-id-type="pmid">28931331</pub-id><pub-id pub-id-type="pmcid">PMC6112117</pub-id></element-citation></ref><ref id="B179-antibodies-12-00041"><label>179.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Dodel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Przybylski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stefanescu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manea</surname><given-names>M.</given-names></name></person-group><article-title>Method of Treatment of Neurodementing Diseases Using Isolated, Monoclonal, Human, Anti-B-Amyloid Antibody</article-title><source>U.S. Patent</source><patent>No. 8,491,903</patent><day>23</day><month>July</month><year>2013</year></element-citation></ref><ref id="B180-antibodies-12-00041"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodel</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Depboylu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fr&#246;lich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haag</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hemmeter</surname><given-names>U.</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teipel</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Brettschneider</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Intravenous immunoglobulins containing antibodies against &#946;-amyloid for the treatment of Alzheimer&#8217;s disease</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2004</year><volume>75</volume><fpage>1472</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2003.033399</pub-id><pub-id pub-id-type="pmid">15377700</pub-id><pub-id pub-id-type="pmcid">PMC1738770</pub-id></element-citation></ref><ref id="B181-antibodies-12-00041"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relkin</surname><given-names>N.</given-names></name></person-group><article-title>Clinical trials of Intravenous Immunoglobulin for Alzheimer&#8217;s disease</article-title><source>J. Clin. Immunol.</source><year>2014</year><volume>34</volume><fpage>S74</fpage><lpage>S79</lpage><pub-id pub-id-type="doi">10.1007/s10875-014-0041-4</pub-id><pub-id pub-id-type="pmid">24760112</pub-id></element-citation></ref><ref id="B182-antibodies-12-00041"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>D.A.</given-names></name></person-group><article-title>Intravenous immunoglobulin and Alzheimer&#8217;s disease: What now?</article-title><source>J. Neuroinflamm.</source><year>2013</year><volume>10</volume><fpage>853</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-10-70</pub-id><pub-id pub-id-type="pmcid">PMC3720252</pub-id><pub-id pub-id-type="pmid">23735288</pub-id></element-citation></ref><ref id="B183-antibodies-12-00041"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Endoplasmic reticulum stress induced by zinc oxide nanoparticles is an earlier biomarker for nanotoxicological evaluation</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>2562</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1021/nn406184r</pub-id><pub-id pub-id-type="pmid">24490819</pub-id></element-citation></ref><ref id="B184-antibodies-12-00041"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>R.A.C.</given-names></name><name name-style="western"><surname>Dalakas</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cornblath</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Latov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weksler</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Relkin</surname><given-names>N.</given-names></name></person-group><article-title>Clinical applications of intravenous immunoglobulins in neurology</article-title><source>Clin. Exp. Immunol.</source><year>2009</year><volume>158</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2009.04025.x</pub-id><pub-id pub-id-type="pmid">19883422</pub-id><pub-id pub-id-type="pmcid">PMC2801030</pub-id></element-citation></ref><ref id="B185-antibodies-12-00041"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>D.A.</given-names></name></person-group><article-title>Erratum: Should development of Alzheimer&#8217;s disease-specific intravenous immunoglobulin be considered?</article-title><source>J. Neuroinflamm.</source><year>2015</year><volume>12</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/s12974-015-0290-z</pub-id><pub-id pub-id-type="pmcid">PMC4389310</pub-id><pub-id pub-id-type="pmid">25880657</pub-id></element-citation></ref><ref id="B186-antibodies-12-00041"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rominger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bartenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>F&#246;rster</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Popp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alferink</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer&#8217;s disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding</article-title><source>Lancet Neurol.</source><year>2013</year><volume>12</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70014-0</pub-id><pub-id pub-id-type="pmid">23375965</pub-id><pub-id pub-id-type="pmcid">PMC4986921</pub-id></element-citation></ref><ref id="B187-antibodies-12-00041"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kile</surname><given-names>S.</given-names></name><name name-style="western"><surname>Au</surname><given-names>W.</given-names></name><name name-style="western"><surname>Parise</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K.</given-names></name><name name-style="western"><surname>Donnel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hankins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>A.</given-names></name></person-group><article-title>IVIG treatment of mild cognitive impairment due to Alzheimer&#8217;s disease: A randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2017</year><volume>88</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2015-311486</pub-id><pub-id pub-id-type="pmid">26420886</pub-id></element-citation></ref><ref id="B188-antibodies-12-00041"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flllit</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Toso</surname><given-names>C.</given-names></name></person-group><article-title>IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ae7aaf</pub-id><pub-id pub-id-type="pmid">19620605</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibodies-12-00041-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of the amyloidogenic APP pathway. APP: amyloid precursor protein; APICD: intracellular domain of the amyloid precursor protein; NFTs: neurofibrillary tangles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibodies-12-00041-g001.jpg"/></fig><fig position="float" id="antibodies-12-00041-f002" orientation="portrait"><label>Figure 2</label><caption><p>Mechanisms of A&#946; clearance by active and passive immunotherapy. A&#946;: &#946;-amyloid; mAb: monoclonal antibody.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="antibodies-12-00041-g002.jpg"/></fig><table-wrap position="float" id="antibodies-12-00041-t002" orientation="portrait"><object-id pub-id-type="pii">antibodies-12-00041-t002_Table 2</object-id><label>Table 2</label><caption><p>Passive immunotherapy clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">A&#946; Passive Immunotherapy Clinical Trials</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target <break/>(A&#946;/Tau)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trial Phase and Status</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunology</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bapineuzumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Janssen/Pfizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG1 <break/>(murine mAb)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N-terminal<break/>(A&#946;1-5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two Phase III studies completed. <break/>Terminated, No improvements<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00606476">NCT00606476</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01254773">NCT01254773</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00996918">NCT00996918</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00676143">NCT00676143</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00998764">NCT00998764</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00667810">NCT00667810</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00575055">NCT00575055</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00574132">NCT00574132</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00916617">NCT00916617</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00112073">NCT00112073</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fc-mediated activation of microglial phagocytosis and cytokine production.<break/>Bind to A&#946; monomers, oligomers, and fibrils.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PII: &#8595;&#8595;CSF t-tau and p-tau while A&#946;-40 and 42 remain unchanged.<break/>PIII: &#8595;&#8595;CSF p-tau. In carriers A&#946;-42 while in non-carriers A&#946;-42, t-tau, and p-tau remain unchanged.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vasogenic cerebral edema.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-antibodies-12-00041" ref-type="bibr">149</xref>,<xref rid="B159-antibodies-12-00041" ref-type="bibr">159</xref>,<xref rid="B160-antibodies-12-00041" ref-type="bibr">160</xref>,<xref rid="B161-antibodies-12-00041" ref-type="bibr">161</xref>,<xref rid="B162-antibodies-12-00041" ref-type="bibr">162</xref>,<xref rid="B163-antibodies-12-00041" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solanezumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eli Lilly (Indianapolis, IN, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG1<break/>(mAb266)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Middle domain (A&#946; 16-24)<break/>(A&#946; monomers) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two Phase III studies were completed; other phases III tests are ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02760602">NCT02760602</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01900665">NCT01900665</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01127633">NCT01127633</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01148498">NCT01148498</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02008357">NCT02008357</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00905372">NCT00905372</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00749216">NCT00749216</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00904683">NCT00904683</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00329082">NCT00329082</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04623242">NCT04623242</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sequestration of soluble monomers of A&#946; thus removes synaptotoxic fragments of A&#946;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PII: &#8593;&#8593;CSF and Serum A&#946;40 and 42 while CSF p-tau and t-tau remain unchanged.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effects on cognition failed to reach clinical outcomes. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-antibodies-12-00041" ref-type="bibr">117</xref>,<xref rid="B160-antibodies-12-00041" ref-type="bibr">160</xref>,<xref rid="B164-antibodies-12-00041" ref-type="bibr">164</xref>,<xref rid="B165-antibodies-12-00041" ref-type="bibr">165</xref>,<xref rid="B166-antibodies-12-00041" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gantenerumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hoffmam- La Rochi (Basel, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N terminal and Mid Domain<break/>(A&#946; 3-12; 18-27)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>Ongoing<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02051608">NCT02051608</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02133937">NCT02133937</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03236844">NCT03236844</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03443973">NCT03443973</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04592341">NCT04592341</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04339413">NCT04339413</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02882009">NCT02882009</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02711423">NCT02711423</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microglia uptake and degradation. Preferentially interacts with fibrillar A&#946;, microglial recruitment, and activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;A&#946; fibrillation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vasogenic edema, discontinued after a futility analysis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-antibodies-12-00041" ref-type="bibr">160</xref>,<xref rid="B167-antibodies-12-00041" ref-type="bibr">167</xref>]<break/>Scarlet <break/>RoAD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01224106">NCT01224106</ext-link>; WN25203)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crenezumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genentech (South San Francisco, CA, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mid-domain (oligomers and fibrils)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III<break/>Ongoing<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03491150">NCT03491150</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03114657">NCT03114657</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02670083">NCT02670083</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02427243">NCT02427243</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01998841">NCT01998841</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01723826">NCT01723826</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02353598">NCT02353598</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IgG4- A&#946; interactions.<break/>Selectively targets A&#946; oligomers and fibrils.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;&#8593;Total plasma A&#946; level, well-tolerated in mild to moderated AD cases.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated vascular risk (B.P, CVD).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-antibodies-12-00041" ref-type="bibr">168</xref>,<xref rid="B169-antibodies-12-00041" ref-type="bibr">169</xref>,<xref rid="B170-antibodies-12-00041" ref-type="bibr">170</xref>,<xref rid="B171-antibodies-12-00041" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ponezumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A&#946; 1-40 (C- terminal amino acids) <break/>(Plasmatic monomer)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>(Halted) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01125631">NCT01125631</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00733642">NCT00733642</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01821118">NCT01821118</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00455000">NCT00455000</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01005862">NCT01005862</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00607308">NCT00607308</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00722046">NCT00722046</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00945672">NCT00945672</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peripheral sink.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe and well-tolerated. <break/>&#8593;&#8593;plasma A&#946; level, &#8593;&#8593;CSF total A&#946; level and free A&#946;-42.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed to reach primary cognitive endpoints.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-antibodies-12-00041" ref-type="bibr">137</xref>,<xref rid="B172-antibodies-12-00041" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aducanumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biogen Idec (Baar, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N terminal and Mid Domain<break/>(A&#946; oligomers and fibrils)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>Ongoing <break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04241068">NCT04241068</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02782975">NCT02782975</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03639987">NCT03639987</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01677572">NCT01677572</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01397539">NCT01397539</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02484547">NCT02484547</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02477800">NCT02477800</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microglial recruitment and activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain penetration occurs and &#8595;&#8595;A&#946; stabilization in MMSE and CDR-sb.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased ARIA chances, usually in APOE e-carriers.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-antibodies-12-00041" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAN2401</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioArtic (Stockholm, Sweden)/Eisai (Nutley, NJ, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Humanized monoclonal IgG1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protofibrils <break/>(&#8805;100 kDa)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II (b)<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01230853">NCT01230853</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02094729">NCT02094729</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01767311">NCT01767311</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selectively targets soluble A&#946; protofibrils.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;CSF-soluble A&#946;. Shows a favorable safety profile.<break/>protofibrils/oligomers.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant adverse effects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-antibodies-12-00041" ref-type="bibr">174</xref>,<xref rid="B175-antibodies-12-00041" ref-type="bibr">175</xref>,<xref rid="B176-antibodies-12-00041" ref-type="bibr">176</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>&#8593;&#8593; (increase), &#8595;&#8595; (decrease).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="antibodies-12-00041-t003" orientation="portrait"><object-id pub-id-type="pii">antibodies-12-00041-t003_Table 3</object-id><label>Table 3</label><caption><p>IVIG immunotherapy clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IVIG Immunotherapy Clinical Trials</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target <break/>(A&#946;/Tau)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trial Phase and Status</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunology</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative Outcomes</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Octagam IVIG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Octapharma (Charlotte, NC, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human polyclonal Ab.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple sites on conformational A&#946; epitopes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>(Completed, No improvement) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02303093">NCT02303093</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00504075">NCT00504075</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02637700">NCT02637700</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00750867">NCT00750867</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01859754">NCT01859754</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01854827">NCT01854827</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00722475">NCT00722475</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased A&#946; clearance by microglia-mediated phagocytosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;A&#946; plaques and plasma A&#946;-42 level.<break/>&#8593;&#8593; cognitive functions. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ischemic stroke and microbleeds.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B182-antibodies-12-00041" ref-type="bibr">182</xref>,<xref rid="B184-antibodies-12-00041" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gammagard IVIG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baxter Healthcare (Deerfield, IL, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human polyclonal Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple sites on conformational A&#946; epitopes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>(Abandoned) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04153422">NCT04153422</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00504075">NCT00504075</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02637700">NCT02637700</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00750867">NCT00750867</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01854827">NCT01854827</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00722475">NCT00722475</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02042027">NCT02042027</ext-link>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased microglial activation and promote A&#946; clearance by phagocytosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safe.<break/>&#8593;&#8593;CSF total A&#946;, <break/>&#8593;&#8593;plasma A&#946; 42 and 40. <break/>&#8595;&#8595;A&#946; fibril and oligomer levels.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No improvement.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-antibodies-12-00041" ref-type="bibr">97</xref>,<xref rid="B182-antibodies-12-00041" ref-type="bibr">182</xref>]<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00818662">NCT00818662</ext-link>)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NewGam</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sutter Health (Sacramento, CA, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human polyclonal Ab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple sites on conformational A&#946; epitopes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>Ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02638207">NCT02638207</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01349790">NCT01349790</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01012323">NCT01012323</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01313507">NCT01313507</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01225276">NCT01225276</ext-link>) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased A&#946; fibril clearance by microglia-mediated phagocytosis. Prevent the formation of soluble A&#946; oligomers.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;&#8595;A&#946; fibril and oligomer levels. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B185-antibodies-12-00041" ref-type="bibr">185</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>&#8593;&#8593; (increase), &#8595;&#8595; (decrease).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>